

CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome e Cognome	Alessandro Antonelli
Data di nascita	04-10-1956
Qualifica	Direttore: Medicina Interna ad indirizzo Immuno-Endocrino Professore Ordinario di Medicina Interna, MD
Amministrazione	Università di Pisa Azienda Ospedaliero-Universitaria Pisana
Incarico attuale	Direttore: Medicina Interna ad indirizzo Immuno-Endocrino, SD, Azienda Ospedaliero-Universitaria Pisana Direttore, Laboratorio Colture Cellulari Umane Primarie, Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa Professore di Medicina Interna, Endocrinologia, Patologia Clinica, Università di Pisa, Scuola di Medicina. Direttore Scuola di Specializzazione in Medicina Interna, Università di Pisa
Numero telefonico dell'ufficio	+39-050-992318
Fax dell'ufficio	+39-050-993472
E-mail istituzionale	alessandro.antonelli@unipi.it

TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE

Titolo di studio	Laurea in Medicina e Chirurgia
Altri titoli di studio e professionali	Specializzazione in Endocrinologia, Medicina del Lavoro, Oncologia
Esperienze professionali (incarichi ricoperti)	• Dal 14 Dicembre 2022 Direttore Scuola di Specializzazione in Medicina Interna, Universit. di Pisa • Dal 14 Dicembre 2016 Direttore SD Medicina Interna ad indirizzo Immuno-Endocrino, Azienda Ospedaliero-Universitaria Pisana • Da Novembre 2015 Dirigente Medico, Responsabile dell'attività endocrinologica, Medicina Interna Universitaria I, Azienda Ospedaliero-Universitaria Pisana • Dal 1 Dicembre 2020 Professore Ordinario di Medicina Interna, Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Universit. di Pisa • 2014-2020 Professore Associato di Medicina Interna, Dipartimento di Medicina Clinica e Sperimentale, Universit. di Pisa • Giugno 2001-2014

	Ricercatore presso il Dipartimento di Medicina Interna, Universit. di Pisa • 1991 – 2001 Tecnico Laureato Medico (Area Tecn. Sc. S. San), Dipartimento di Medicina Interna, Universit. di Pisa • 1988 – 1990 Assistente Medico USL-15- Alta Val di Cecina di Volterra • Luglio – Settembre 1988 Assistente medico a Contratto USL-15- Alta Val di Cecina di Volterra						
Capacità linguistiche	<table><tr><td>Lingua</td><td>Livello Parlato</td><td>Livello Scritto</td></tr><tr><td>Inglese</td><td>Ottimo</td><td>Ottimo</td></tr></table>	Lingua	Livello Parlato	Livello Scritto	Inglese	Ottimo	Ottimo
Lingua	Livello Parlato	Livello Scritto					
Inglese	Ottimo	Ottimo					
Capacità nell’uso delle Tecnologie	Ottima capacità nell'utilizzo delle tecnologie di vario genere						
Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione utile alla pubblicazione)	Titoli Accademici Idoneo per: Prima Fascia (Professore Ordinario): 06/B1 Medicina Interna - Abilitazione Scientifica Nazionale 2016-2018 06/D2 Endocrinologia, Nefrologia, Scienze Alimentazione, etc. -Abilitazione Scientifica Nazionale 2016-2018 06/N1 Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate - Abilitazione Scientifica Nazionale 2016-2018 06/D3 Malattie del Sangue, Oncologia e Reumatologia - Abilitazione Scientifica Nazionale 2016-2018 Idoneo per: Prima Fascia (Professore Ordinario): 06/D2 Endocrinologia, Nefrologia, Scienze Alimentazione, etc. -Abilitazione Scientifica Nazionale 2013 06/A2 Patologia Generale e Patologia Clinica- Abilitazione Scientifica Nazionale 2012 2010-2012 Membro della Commissione Scientifica dell'Università di Pisa (Area 06, Medicina) 2012-2014 Membro della Commissione Scientifica dell'Università di Pisa (Area 06, Medicina) 2017-2018 Membro della Commissione Scientifica dell'Università di Pisa (Area 06, Medicina) 2020-in corso Membro della Commissione Scientifica dell'Università di Pisa (Area 06, Medicina) Da Settembre 2019; Vice presidente del personale medico universitario del “Consiglio dei Sanitari, AOUP”, Pisa Dal 2023 Presidente della Commissione Scientifica dell'Università di Pisa (Area 06, Medicina) Partecipazione al collegio dei docenti ovvero attribuzione di incarichi di insegnamento, nell'ambito di dottorati di ricerca accreditati dal Ministero: - Ha svolto attività didattica presso il corso di Dottorato in “Scienze Cliniche e Traslazionali”, dell'Università di Pisa (da 17-09-2013 al 31-10-2018). - Adesione al Dottorato dal titolo “Fisiopatologia Clinica” dell'Università di Pisa (dal 02-03-2018 ad oggi).						

Grants. Direzione o partecipazione alle attività di un gruppo di ricerca caratterizzato da collaborazioni a livello nazionale o internazionale

A) Ha seguito personalmente gli aspetti medico-endocrinologici e bio-molecolari dei bambini Bielorussi affetti da carcinoma della tiroide secondario all'incidente di Chernobyl negli anni 93-99; questa attività ha portato alla stesura del protocollo di collaborazione tra la Azienda Ospedaliera Pisana e il Ministero della Sanità Bielorosso (1995-1997), a cui ha partecipato in prima persona, per la cura dei bambini Bielorussi affetti da carcinoma della tiroide dopo l'incidente di Chernobyl, che ha portato alla pubblicazione dei seguenti lavori:

1. Bruno RM, Sicari R, Corciu AI, Bianchini E, Faita F, Di Stefano R, Antonelli A, Ghiadoni L, Picano E. Non-cancer atherosclerotic effects associated with environmental and therapeutic radiation doses: the Chernobyl thyroid cancer children study. *Int J Cardiol.* 2013 Oct 9;168(4):4255-7. doi: 10.1016/j.ijcard.2013.04.161. No abstract available.
2. Antonelli A, Fallahi P, Grosso M, Boni G, Minuto MN, Miccoli P. Lobectomy versus total thyroidectomy in children with post-Chernobyl thyroid cancer: a 15 year follow-up. *Endocrine.* 2011 Dec;40(3):432-6. doi: 10.1007/s12020-011-9500-3.
3. Spinelli C, Bertocchini A, Antonelli A, Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. *J Pediatr Surg.* 2004 Oct;39(10):1500-5.
4. Frenzilli G, Bosco E, Antonelli A, Panasiuk G, Barale R. DNA damage evaluated by alkaline single cell gel electrophoresis (SCGE) in children of Chernobyl, 10 years after the disaster. *Mutat Res.* 2001 Apr 5;491(1-2):139-49.
5. Gemignani F, Ballardini M, Maggiani F, Rossi AM, Antonelli A, Barale R. Chromosome aberrations in lymphocytes and clastogenic factors in plasma detected in Belarus children 10 years after Chernobyl accident. *Mutat Res.* 1999 Dec 13;446(2):245-53.
6. Roberto B, Gemignani F, Morizzo C, Lori A, Rossi A, Antonelli A, Di Pretoro G, Panasiuk G, Ballardini M. Cytogenetic damage in lymphocytes of healthy and thyroid tumor-affected children from the Gomel region (Belarus). *Mutat Res.* 1998 Aug 31;405(1):89-95.
7. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. *Arch Surg.* 1998 Jan;133(1):89-93.
8. Antonelli A, Miccoli P, Derzhitski VE, Panasiuk G, Solovieva N, Baschieri L. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). *World J Surg.* 1996 Sep;20(7):867-71.

B) Ha dimostrato (per la prima volta) la presenza di anticorpi anti-CD38 in pazienti con diabete di tipo 1 o 2, con tiroidite cronica o Morbo di Basedow, dimostrando anche che gli anticorpi anti-CD38 sono in grado di aumentare il calcio intracellulare nelle cellule-beta umane, promuovendo la secrezione insulinica. Queste ricerche sono state finanziate:

- 1- dalla Juvenile Diabetes Foundation (USA) (# 5-2000-536);
- 2- dalla Yamanouchi Foundation (Japan-Europe).

Queste ricerche hanno portato alla pubblicazione dei seguenti lavori, in collaborazione con Okamoto H, Tuomi T, Groop L:

1. Pupilli C, Antonelli A, Iughetti L, D'Annunzio G, Cotellessa M, Vanelli M, Okamoto H, Lorini R, Ferrannini E. Anti-CD38 autoimmunity in children with newly diagnosed type 1 diabetes mellitus. *J Pediatr Endocrinol Metab.* 2005 Dec;18(12):1417-23.
2. Antonelli A, Ferrannini E. CD38 autoimmunity: recent advances and relevance to human diabetes. *J Endocrinol Invest.* 2004 Jul-Aug;27(7):695-707. Review.
3. Marchetti P, Antonelli A, Lupi R, Marselli L, Fallahi P, Nesti C, Baj G, Ferrannini E. Prolonged in vitro exposure to autoantibodies against CD38 impairs the function and survival of human pancreatic islets. *Diabetes.* 2002 Dec;51 Suppl 3:S474-7.
4. Antonelli A, Tuomi T, Nannipieri M, Fallahi P, Nesti C, Okamoto H, Groop L, Ferrannini E. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. *Diabetologia.* 2002 Sep;45(9):1298-306.
5. Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Okamoto H, Ferrannini E. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. *Clin Exp Immunol.* 2001 Dec;126(3):426-31.
6. Antonelli A, Baj G, Marchetti P, Fallahi P, Surico N, Pupilli C, Malavasi F, Ferrannini E. Human anti-CD38 autoantibodies raise intracellular calcium and

stimulate insulin release in human pancreatic islets. Diabetes. 2001 May;50(5):985-91.

7. Pupilli C, Giannini S, Marchetti P, Lupi R, Antonelli A, Malavasi F, Takasawa S, Okamoto H, Ferrannini E. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes. 1999 Dec;48(12):2309-15.

Responsabile di progetti di ricerca

- Responsabile Scientifico della Unità di Ricerca (PRIN-2002) "Valutazione degli effetti metabolici della 3,5-T2 nell'uomo, in acuto (in paragone a L-T3 o L-T4), o mediante somministrazione prolungata".
- Responsabile Scientifico della Unità di Ricerca (PRIN-2004) "Effetti della 3,5-T2 in pazienti con obesità, o ipercolesterolemia LDL, o ipertrigliceridemia, o steatosi epatica".
- Responsabile Scientifico della Unità di Ricerca (PRIN-2006) "Effetto della 3,5-T2 e della T3 sulla adiposità nell'uomo: meccanismi cellulari".
- Responsabile Scientifico della Unità di Ricerca (PRIN-2008) "Valutazione dell'attività di nuovi inibitori delle tirosin chinasi e delle chinasi aurora in cellule primarie di carcinoma midollare umano".
- Responsabile Scientifico della Unità di Ricerca (PRIN-2010-2011) "Carcinoma papillare e midollare della tiroide non curabile con le terapie convenzionali: caratteristiche clinico-epidemiologiche, sintesi, farmacologia preclinica, target-therapy di nuovi agenti inibitori delle tirosin-chinasi e delle chinasi aurora in colture cellulari primarie umane".

Altri Progetti

- Responsabile Scientifico di Unità del progetto AIRC Investigator Grant (IG) 2010 dal titolo: "Antineoplastic activity of PPARalpha agonists in aggressive and not radioiodine responsive thyroid cancers".
- Responsabile Scientifico del progetto risultato vincitore (luglio 2012) di un bando della Facoltà di Medicina e Chirurgia (Università di Pisa) rivolto ai ricercatori della Facoltà stessa, ricevendo un finanziamento per l'espletamento della ricerca dal titolo: "Valutazione dell'effetto immunomodulante della genisteina sui tireociti e preadipociti umani, e dell'effetto anti-neoplastico nel carcinoma tiroideo".
- Responsabile Scientifico di Unità dello studio dal titolo "Periodontal disease as emergent systemic pathology: development of a new clinical unit for patients global health care" nell'ambito del "Bando Ricerca Finalizzata 2009", come Investigatore Principale, insieme al Prof Filippo Graziani, attualmente Prof Ordinario, Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa, per il Ministero della Salute.
- Ha partecipato a livello internazionale all'attività del seguente gruppo di ricerca:
 - "International Study Group of Extrahepatic Manifestations Related to Hepatitis C Virus Infection (ISG-EHCV)", che ha portato alla pubblicazione del seguente lavoro: Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, House M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV coauthors. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016 Dec; 15 (12): 1145-1160.
- Responsabile Scientifico del progetto PRA 2016 - Bando per il finanziamento di Progetti di Ricerca di Ateneo (Università di Pisa) dal titolo: "Effetti della 3,5-diiodo-L-tironina, su cellule tiroidee, beta-insulari ed adipociti umani, vs T3".
- Responsabile Scientifico del progetto di ricerca dal titolo: "Studio degli effetti, e dei meccanismi cellulari, implicati nella azione di 3,5-diiodotironina (T2), e della triiodotironina (T3), in cellule umane" (2017-2019).

Clinical Trials recenti

- Principal Investigator del gruppo di ricerca dell'Università di Pisa: Studio di fase 2, multicentrico, randomizzato, in doppio cieco, internazionale, dal titolo: "A randomized, double-masked, placebo-controlled, efficacy and

safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)” (2015-2017), che ha portato alla stesura del lavoro sottoindicato che è stato pubblicato su New England J Medicine:

“Teprotumumab for Thyroid-Associated Ophthalmopathy” Terry J Smith, George J Kahaly, Daniel G Ezra, James C Fleming, Roger A Dailey, Rosa A Tang, Gerald J Harris, Alessandro Antonelli, Mario Salvi, Robert A Goldberg, James W Gigantelli, Steven M Couch, Erin M Shriver, Brent R Hayek, Eric M Hink, Richard M Woodward, Kathleen Gabriel, Guido Magni, Raymond S Douglas (N Engl J Med. 2017 May 4;376(18):1748-1761).

- Partecipazione in qualità di Principal Investigator allo studio sperimentale dal titolo: “A phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease”, presso il Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa (2018-2021), che ha portato alla stesura del lavoro sottoindicato che è stato pubblicato su New England J Medicine:

“Teprotumumab for the Treatment of Active Thyroid Eye Disease” Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. (N Engl J Med. 2020 Jan 23;382(4):341-352.)

- Partecipazione in qualità di Principal Investigator allo studio sperimentale dal titolo: “Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Thyroid Eye Disease” (2019-2021), che ha portato alla stesura del lavoro sottoindicato che è stato pubblicato su Ophthalmology:

“Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.” Raymond S Douglas, George J Kahaly, Shoaib Ugradar, Heike Elflein, Katharina A Ponto, Brian T Fowler, Roger Dailey, Gerald J Harris, Jade Schiffman, Rosa Tang, Sara Wester, Amy Patel Jain, Claudio Marcocci, Michele Marinò, Alessandro Antonelli, Anja Eckstein, Dagmar Führer-Sakel, Mario Salvi, Saba Sile, Megan Francis-Sedlak, Robert J Holt, Terry J Smith. (Ophthalmology. 2021 Oct 21;S0161-6420(21)00818-6. doi: 10.1016/j.optha.2021.10.017.)

- Principal Investigator dello studio clinico sperimentale dal titolo: “Retrospective evaluation of thyroid hormonal profile in hypothyroid patients treated with L-T4 in different formulations (tablet, liquid formulation, soft capsule) for a period longer than 1 year” (18/03/2020 – 30/09/2023).

- Principal investigator dello studio clinico sperimentale dal titolo: “A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab” (04/08/2022– in corso).

- Principal Investigator dello studio clinico dal titolo “Acute and long-term impact of COVID- 19 in patients with systemic, or organ-specific, autoimmune diseases in relation to subsequent pandemic waves, COVID variants, and vaccinations; with particular reference to the efficacy and long-term effects of vaccinations on autoimmune disease activity” (Ricerca Finalizzata 2021 – Ministero della Salute; 28/04/2023 – in corso).

- Principal Investigator dello studio clinico sperimentale dal titolo “A phase 2b, randomized, double-mask, placebo-controlled, study to evaluate the safety, pharmacokinetics and efficacy of linsitinib in subjects with active, moderate to severe thyroid eye disease (TED)” (03/05/2023 – in corso)

- Principal investigator dello studio clinico sperimentale dal titolo “IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)” (20/07/2023 – in corso).

- Principal investigator dello studio clinico sperimentale dal titolo “IMVT-1401-3203: An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)” (20/07/2023 – in corso).

Aree di interesse scientifico

Ha studiato l'effetto terapeutico ed immunomodulatore della somministrazione di immunoglobuline endovena ad alto dosaggio, nelle tireopatie autoimmuni, nel morbo di Basedow e nella oftalmopatia Basedowiana.

Ha dimostrato (per la prima volta) la presenza di anticorpi anti-CD38 in pazienti con diabete di tipo 1 o 2, con tiroidite cronica o Morbo di Basedow, dimostrando anche che gli anticorpi anti-CD38 sono in grado di aumentare il calcio intracellulare nelle cellule-beta umane, promuovendo la secrezione insulinica. Queste ricerche sono state finanziate:

- 1- dalla Juvenile Diabetes Foundation (USA) (#5-2000-536);
- 2- dalla Yamanouchi Foundation (Japan-Europe).

Ha studiato e dimostrato l'associazione tra infezione cronica da HCV, o crioglobulinemia mista o lupus eritematoso sistemico e carcinoma papillare della tiroide, autoimmunità tiroidea e diabete, e studiato l'immunopatogenesi di questa associazione, e della secrezione delle chemochine.

Ha dimostrato (per la prima volta) l'importanza delle chemochine inducibili da interferon-gamma (CXCL10, CXCL9 e CXCL11) e della chemochina (Th2) CCL2, nella patogenesi delle tiroidite di Hashimoto, nel morbo di Graves', nella Oftalmopatia Basedowiana, nel diabete di tipo 1, nella sclerosi sistemica e nella crioglobulinemia mista.

Ha studiato l'effetto delle citochine (interferon-gamma, TNFalfa, etc) sulla secrezione delle chemochine in cellule primarie umane ottenute da pazienti affetti da Morbo di Graves, Oftalmopatia Basedowiana, Crioglobulinemia e Sclerosi Sistemica.

Ha dimostrato (per la prima volta) l'efficacia di nuovi farmaci inibitori delle tirosin-chinasi nel carcinoma tiroideo. Queste ricerche sono state ritenute meritevoli di interesse e di essere finanziate dal Ministero dell'Università e Della Ricerca.

Dal 2001 al 2011, ha ricevuto grants dal Ministero dell'Università e Della Ricerca, per le ricerche sopra menzionate.

Dal 2013, ancora in corso, ha trattato più di 1000 pazienti affetti da ipotiroidismo con L-T4 in formulazione liquida e più di 300 pazienti con L-T4 in capsule soft-gel.

Ha pubblicato la più ampia casistica di pazienti (senza problemi di malassorbimento) trattati con L-T4 liquida.

Si noti inoltre che le revisioni e la meta-analisi, i risultati degli studi condotti dal Prof. Antonelli et al, hanno un peso importante e prevalente sulla letteratura già esistente.

Qui sotto sono riportate le pubblicazioni di cui sopra:

1. Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal Malabsorption of Thyroxine. *Endocr Rev.* 2019 Feb 1;40(1):118-136.
2. Fallahi P, Ferrari SM, Materazzi G, Ragusa F, Ruffilli I, Patrizio A, Miccoli P, Antonelli A. Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study. *Laryngoscope Investig Otolaryngol.* 2018 Oct 3;3(5):405-408.
3. Benvenga S, Capodicasa G, Perelli S, Ferrari SM, Fallahi P, Antonelli A. Increased Requirement of Replacement Doses of Levothyroxine Caused by Liver Cirrhosis. *Front Endocrinol (Lausanne).* 2018 Apr 18;9:150.
4. Virili C, Giovanella L, Fallahi P, Antonelli A, Santaguida MG, Centanni M, Trimboli P. Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne).* 2018 Jan 26;9:10.

5. Fallahi P, Ferrari SM, Antonelli A. IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM. *Endocr Pract.* 2017 Feb;23(2):170-174.
6. Fallahi P, Ferrari SM, Marchi S, De Bortoli N, Ruffilli I, Antonelli A. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. *Endocrine.* 2017 Jul;57(1):175-178.
7. Fallahi P, Ferrari SM, Ruffilli I, Ragusa F, Biricotti M, Materazzi G, Miccoli P, Antonelli A. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update. *Expert Opin Drug Deliv.* 2017 May;14(5):647-655.
8. Fallahi P, Ferrari SM, Camastra S, Politti U, Ruffilli I, Vita R, Navarra G, Benvenga S, Antonelli A. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation. *Obes Surg.* 2017 Jan;27(1):78-82.
9. Fallahi P, Ferrari SM, Ruffilli I, Antonelli A. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. *BMC Gastroenterol.* 2016 Feb 24;16:22.
10. Fallahi P, Ferrari SM, Antonelli A. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. *Endocrine.* 2016 Jun;52(3):597-601.
11. Vita R, Fallahi P, Antonelli A, Benvenga S. The administration of L-thyroxine as soft gel capsule or liquid solution. *Expert Opin Drug Deliv.* 2014 Jul;11(7):1103-11.

Ha dimostrato per la prima volta che la 3,5-T2 riduce il grasso corporeo ed il peso nell'Uomo (l'unico studio pubblicato nell'Uomo ad oggi), e ha dimostrato per la prima volta l'effetto stimolatorio della T2 nelle insule umane (l'unico studio pubblicato nelle cellule umane ad oggi).

Pubblicazioni al riguardo:

1. Fallahi P, Ferrari SM, Santini E, Camastra S, Frenzilli G, Puccini M, Goglia F, Lanni A, Marchetti P, Antonelli A. Both 3,5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion. *J Biol Regul Homeost Agents.* 2017 Apr-Jun;31(2):503-508.
2. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. *J Biol Regul Homeost Agents.* 2011 Oct-Dec;25(4):655-60.
3. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, Lanni A, Cavaliere G, Barletta A, Goglia F. 3,5-diiodo-L-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. *J Hepatol.* 2009 Aug;51(2):363-70.
4. Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Baccari GC, Fallahi P, Antonelli A, Goglia F. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. *FASEB J.* 2005 Sep;19(11):1552-4.

Recenti AWARDS

- Award in "recognition of outstanding contributions given by Prof. Alessandro Antonelli, University of Pisa, in the field of endocrine and systemic autoimmune disorders, their associations, and the importance of chemokines in the pathogenesis of endocrine, systemic and rheumatological disorders" dal Prof Shoenfeld Yehuda, in qualità di Editor-in-Chief, *Autoimmunity Reviews Journal* (IF = 13,6)
- Award in "recognition of outstanding contributions given by Prof. Alessandro Antonelli, University of Pisa, in the field of endocrine and systemic autoimmune disorders, their associations, and the importance of chemokines in the pathogenesis of endocrine, systemic and

rheumatological disorders", conferito al "The 3rd International Congress on Controversies in Rheumatology & Autoimmunity" (CORA 2015); Sorrento, Italia, 12-14 Marzo 2015

- Award in "recognitions of the outstanding contribution given by Prof. Alessandro Antonelli University of Pisa in the field of "thyroid cancer therapy", and of "Endocrine and Systemic Autoimmune Disorders", their associations, and their pathogenesis" dalla "World Academy of Sciences" (Febbraio 2019)
- Award in recognition of the outstanding contributions given "in the field of thyroid autoimmune disorders, their associations with systemic autoimmune diseases, and with thyroid cancer, and the importance of viral infections, and cytokines/chemokines network, in the their pathogenesis", from "International Academy of Autoimmunity", San Pietroburgo (Ottobre 2019).

Lista delle Pubblicazioni

Il Prof. Antonelli ha pubblicato più di 400 lavori su riviste scientifiche internazionali con IF. Impacr Factor>1700, H index 84 (Scopus and ISI, ASN).

1. Pacini F, **Antonelli A**, Lari R, Gasperini L, Baschieri L, Pinchera A. Unsuspected parathyroid cysts diagnosed by measurement of thyroglobulin and parathyroid hormone concentrations in fluid aspirates. *Ann Intern Med.* 1985 Jun;102(6):793-794.
2. Martino E, Macchia E, Aghini-Lombardi F, **Antonelli A**, Lenziardi M, Concetti R, Fenzi GF, Baschieri L, Pinchera A. Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis? *Clin Endocrinol.* 1986;24:627-633.
3. Bartalena L, Martino E, **Antonelli A**, Pacchiarotti A, Robbins J, Pinchera A. Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells. *Endocrinology.* 1986;119(3):1185-1188.
4. Benvenga S, Bartalena L, **Antonelli A**, Li Calzi L, Di Pasquale G, Trimarchi F, Pinchera A. Radioimmunoassay for human thyroxine-binding prealbumin. *Ann Clin Lab Sci.* 1986 May-Jun;16(3):231-240.
5. Baschieri L, **Antonelli A**, Del Guerra P. Therapeutic strategy in thyroid carcinoma. *Clin Ter.* 1987 Jun 30;121(6):457-465.
6. **Antonelli A**, Del Guerra P, Baschieri L. Somatostatin-induced changes in the secretion of insulin, glucagon and gastrin in functional hypoglycemia. *Minerva Endocrinol.* 1987 Oct-Dec;12(4):281-288.
7. Bartalena L, Fenzi G, Vitti P, Tombaccini D, **Antonelli A**, Macchia E, Chiovato L, Kohn LD, Pinchera A. Interaction of the thyrotropin receptor on rat FRTL-5 thyroid cells with thyrotropin and a thyrotropin-stimulating autoantibody from Graves' patients. *Biochem Biophys Res Commun.* 1987 Feb 27;143(1):266-272.
8. **Antonelli A**, Del Guerra P, Fierabracci A, Gori E, Baschieri L. Effect of salmon calcitonin on symptoms and urinary excretion of 5 hydroxyindoleacetic acid in the carcinoid syndrome. *Br Med J (Clin Res Ed).* 1987 Oct 17;295(6604):961.
9. **Antonelli A**, Del Guerra P, Baschieri L. Calcitonin and somatostatin effect in carcinoid syndrome. *The Italian Journal of Gastroenterology (Digestive and Liver Diseases).* 1988;20:137-139.
10. Baschieri L, Castagna M, Fierabracci A, **Antonelli A**, Del Guerra P, Squartini F. Distribution of calcitonin- and somatostatin-containing cells in thyroid lymphoma and in Hashimoto's thyroiditis. *Appl Pathol.* 1989;7(2):99-104.
11. Donati L, Venturi S, Andreani M, **Antonelli A**, Gori E, Bertoni F, Pruneti CA, Berrettini S, Bruschini P, Baschieri L. Audiological and neuropsychological development study in a sample of school children from a low-iodine area of the Central Apennines that is endemic for cretinism. *Minerva Endocrinol.* 1989 Apr-Jun;14(2):99-103.
12. Baschieri L, **Antonelli A**, del Guerra P, Fialdini A, Gasperini L. Somatostatin effect in postprandial hypoglycemia. *Metabolism.* 1989 Jun;38(6):568-571.
13. Palla R, Cirami C, Panichi V, Bianchi AM, Parrini M, Barsotti G, Cupisti A,

- Moriconi L, Puccini R, Paleologo G, Cioni L, **Antonelli A**, Giusti R, Chimienti S, Cristofano C, Dall'Aglia PP, Tamperi E, Bellucci G, L'Abbate A. Treatment of idiopathic membranous nephropathy (MGN) with high dose intravenous gammaglobulin: Results of a multicenter non-randomized and non-controlled trial. *Journal of Nephrology*, 4, (4), 1991:211-219.
14. Donati L, Antonelli A, Andreani M, Venturi S, Pruneti CA, Berrettini S, Baschieri L. Persistenza di aree di gozzo-cretinismo endemico in Italia. Il caso del Montefeltro. Importanza dell'apporto iodico e della funzione tiroidea sullo sviluppo dell'SNC nell'uomo. *Giornale Di Clinica Medica*. 1991;72:39-48.
15. **Antonelli A**, Saracino A, Alberti B, Melosi A, Cartei F, Lepri A, Laddaga M, Baschieri L. The combined therapy of Basedow's ophthalmopathy with retrobulbar radiotherapy and i.v. immunoglobulins. The preliminary results. *Clin Ter*. 1992 Jan;140(1):25-31.
16. Carmassi F, Morale M, Puccetti R, Pistelli F, Palla R, Bevilacqua G, Viacava P, **Antonelli A**, Mariani G. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. *Clin Exp Rheumatol*. 1992 Jan Feb;10(1):13-17.
17. **Antonelli A**, Saracino A, Alberti B, Canapicchi R, Cartei F, Lepri A, Laddaga M, Baschieri L. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. *Acta Endocrinol (Copenh)*. 1992 Jan;126(1):13-23.
18. **Antonelli A**, Gambuzza C, Bertoni F, Baschieri L. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide. *Clin Ther*. 1992 Mar-Apr;14(2):178-184.
19. **Antonelli A**, Saracino A, Agostini S, Alberti B, Melosi A, Gambuzza C, Avantaggiato G, Baschieri L. Results of high-dose intravenous immunoglobulin treatment of patients with pretibial myxedema and Basedow's disease. Preliminary findings. *Clin Ter*. 1992 Sep;141(9 Pt 2):63-68.
20. **Antonelli A**, Palla R, Casarosa L, Alberti B, Saracino A, Baschieri L. In vitro solubilization of deposits of IgG immune complexes by gamma-globulins in patients with Graves' disease, Graves' ophthalmopathy, pretibial myxoedema and Hashimoto's thyroiditis. *Pharmacol Res*. 1992 Sep;26 Suppl 2:170-171.
21. **Antonelli A**, Carmassi F, Neri S, Saracino A, Gambuzza C, Alberti B, Baschieri L. Inappropriate antidiuretic hormone secretion in a patient with systemic sarcoidosis. *Recenti Prog Med*. 1992 Sep;83(9):492-495.
22. Agostini G, **Antonelli A**. Intravenous immunoglobulins. General features and the main clinical applications. *Clin Ter*. 1992 Sep;141(9 Pt 2):17-32.
23. **Antonelli A**, Agostini G, Agostini S. Preliminary results of intravenous immunoglobulins in treating patients with vasculitis. *Clin Ter*. 1992 Sep;141(9 Pt 2):33-36.
24. **Antonelli A**, Alberti B, Melosi A, Saracino A, Agostini S, Gambuzza C, Neri S, Baschieri L. Changes in markers of autoimmunity in patients with Hashimoto thyroiditis treated with intravenous immunoglobulins. Preliminary results. *Clin Ter*. 1992 Sep;141(9 Pt 2):37-42.
25. **Antonelli A**, Gambuzza C, Alberti B, Saracino A, Melosi A, Agostini S, Blunda P, Baschieri L. Autoimmune polyendocrine syndrome. Treatment with intravenous immunoglobulins. *Clin Ter*. 1992 Sep;141(9 Pt 2):43-48.
26. **Antonelli A**, Melosi A, Saracino A, Alberti B, Agostini S, Neri S, Gambuzza C, Biondi L, Baschieri L. Parameters of organ-specific and non-specific autoimmunity in patients with Basedow's disease and Basedow's ophthalmopathy. Changes induced by IVIG treatment. *Clin Ter*. 1992 Sep;141(9 Pt 2):49-54.
27. **Antonelli A**, Neri S, Gasperini L, Alberti B, Saracino A, Gambuzza C, Agostini S, Baschieri L. Liver function tests, hepatitis A, B, C markers and HIV antibodies in patients with Basedow's ophthalmopathy treated with intravenous immunoglobulins. *Clin Ter*. 1992 Sep;141(9 Pt 2):55-61.
28. Donati L, **Antonelli A**, Bertoni F, Moscogiuri D, Andreani M, Venturi S, Filippi T, Gasperini L, Neri S, Baschieri L. Clinical picture of endemic cretinism in central Apennines (Montefeltro). *Thyroid*. 1992; 2 (4):283-290.
29. Baschieri L, **Antonelli A**. Intravenous immunoglobulin treatment in Graves' Ophthalmopathy. *Acta Endocrinologica* 1992; 126:474. Letter.
30. **Antonelli A**, Gambuzza C, Bertoni F, Baschieri L. Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome. *J Endocrinol Invest*. 1993 Jan;16(1):57-59.
31. **Antonelli A**, Carmassi F, Alberti B, Gambuzza C, Neri S, Saracino A, Baschieri L. Demeclocycline-induced phosphate diabetes in a patient with

inappropriate ADH secretion and systemic sarcoidosis. *Nephron*. 1993;63(2):226-229.

32. Falaschi F, Boraschi P, **Antonelli A**, Neri S, Bartolozzi C. Diagnosis with high resolution computerized tomography of early asbestos-induced diseases. *Radiol Med (Torino)*. 1993 Sep;86(3):220-226.

33. Miccoli P, **Antonelli A**, Iacconi P, Alberti B, Gambuzza C, Baschieri L. Prospective, randomized, double-blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow-up. *Surgery*. 1993 Dec;114(6):1097-1101.

34. **Antonelli A**, Navarranne A, Palla R, Alberti B, Saracino A, Mestre C, Roger P, Agostini S, Baschieri L. Pretibial myxedema and high-dose intravenous immunoglobulin treatment. *Thyroid*. 1994 Winter;4(4):399-408.

35. Neri S, **Antonelli A**, Falaschi F, Boraschi P, Baschieri L. Findings from high resolution computed tomography of the lung and pleura of symptom free workers exposed to amosite who had normal chest radiographs and pulmonary function tests. *Occup Environ Med*. 1994 Apr;51(4):239-243.

36. Alberti B, Campatelli A, **Antonelli A**, Di Vito A, Francese C, Saracino A, Agostini S, Baschieri L. Review of a case series of cervical cysts and evaluation of the efficacy of sclerotherapy with tetracycline hydrochloride in thyroid cystic lesions. *Clin Ter*. 1994 Jul;145(7):27-33.

37. Neri S, **Antonelli A**, Boraschi P, Falaschi F, Rizzini D, Baschieri L. Asbestos-related lesions detected by high-resolution CT scanning in asymptomatic workers. Specificity, relation to the duration of exposure and cigarette smoking. *Clin Ter*. 1994 Aug;145(8):97-106.

38. **Antonelli A**, Campatelli A, Di Vito A, Alberti B, Baldi V, Salvioni G, Fallahi P, Baschieri L. Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts. *Clin Investig*. 1994 Dec;72(12):971-974.

39. **Antonelli A**, Miccoli P, Ferdeghini M, Di Coscio G, Alberti B, Iacconi P, Baldi V, Fallahi P, Baschieri L. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. *Thyroid*. 1995 Feb;5(1):25-28.

40. **Antonelli A**, Silvano G, Bianchi F, Gambuzza C, Tana L, Salvioni G, Baldi V, Gasperini L, Baschieri L. Risk of thyroid nodules in subjects occupationally exposed to radiation: a cross sectional study. *Occup Environ Med*. 1995 Aug;52(8):500-504.

41. Falaschi F, Boraschi P, Neri S, **Antonelli A**, Rizzini D, Battolla L. High resolution Computed Tomography (HRCT) in the detection of "early asbestosis". *European Radiology*. 1995;5:291-296.

42. Falaschi F, Battolla L, Mascacchi M, Cioni R, Zampa V, Lencioni R, **Antonelli A**, Bartolozzi C. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. *AJR Am J Roentgenol*. 1996 Apr;166(4):963-968.

43. Iacconi P, **Antonelli A**, Monzani F, Bendinelli C, Ricci E, Miccoli P. La opoterapia post chirurgica nei pazienti operati per struma multinodulare. *Annali Italiani Di Chirurgia*. 1996; 67:347-350.

44. **Antonelli A**, Silvano G, Gambuzza C, Bianchi F, Tana L, Baschieri L. Is occupationally induced exposure to radiation a risk factor of thyroid nodule formation? *Arch Environ Health*. 1996 May-Jun;51(3):177-180.

45. **Antonelli A**, Palla R, Casarosa L, Fallahi P, Baschieri L. IgG, IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves' disease: their in vitro solubilization by intravenous immunoglobulin. *Clin Exp Rheumatol*. 1996 May-Jun;14 Suppl 15:S31-35.

46. Iacconi P, **Antonelli A**, Monzani F, Bendinelli C, Ricci E, Miccoli P. Postoperative organotherapy for multinodular goiter *Ann Ital Chir*. 1996 May-Jun;67(3):347-350.

47. **Antonelli A**, Miccoli P, Derzhitski VE, Panasiuk G, Solovieva N, Baschieri L. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). *World J Surg*. 1996 Sep;20(7):867-871.

48. Falaschi F, Battolla L, Zampa V, Cioni R, Cambi L, **Antonelli A**, Bartolozzi C. CT versus MRI in the differentiation of benign from malignant pleural disease [Confronto fra tomografia computerizzata e risonanza magnetica nella valutazione delle malattie pleuriche benigne e maligne]. *Radiologia Medica (Torino)*. 1996 Dec;92(6):713-718.

49. **Antonelli A**, Bombardieri S, Fallahi P, Kotopulos CDA, Battaglia S, Baschieri L. Thyroid and non organ specific autoantibodies in patients with thyroid-associated ophthalmopathy. *Orbit*. 1996; 15 (3):213-219.

50. **Antonelli A**, Silvano G, Bianchi F, Gambuzza C, Tana L, Fallahi P, Baschieri L. Reply to the comments on Risk of thyroid nodules in subject occupationally exposed to radiation: a cross sectional study. *Occupational and Environmental Medicine*. 1996; 53: 575.
51. Neri S, Boraschi P, **Antonelli A**, Falaschi F, Baschieri L. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. *Am J Ind Med*. 1996 Nov;30(5):588-95.
52. Baschieri L, **Antonelli A**, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallahi P. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. *Thyroid*. 1997 Aug;7(4):579-585.
53. Miccoli P, **Antonelli A**, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. *Arch Surg*. 1998 Jan;133(1):89-93.
54. Barale R, Gemignani F, Morizzo C, Lori A, Rossi A, **Antonelli A**, Di Pretoro G, Panasiuk G, Ballardini M. Cytogenetic damage in lymphocytes of healthy and thyroid tumor-affected children from the Gomel region (Belarus). *Mutat Res*. 1998 Aug 31;405(1):89-95.
55. **Antonelli A**, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. *JAMA*. 1999 May 5;281(17):1588.
56. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, **Antonelli A**, Nannipieri M, Mari A, Seghieri G, Natali A. Insulin: new roles for an ancient hormone. *Eur J Clin Invest*. 1999 Oct;29(10):842-852.
57. Pupilli C, Giannini S, Marchetti P, Lupi R, **Antonelli A**, Malavasi F, Takasawa S, Okamoto H, Ferrannini E. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. *Diabetes*. 1999 Dec;48(12):2309-2315.
58. Gemignani F, Ballardini M, Maggiani F, Rossi AM, **Antonelli A**, Barale R. Chromosome aberrations in lymphocytes and clastogenic factors in plasma detected in Belarus children 10 years after Chernobyl accident. *Mutat Res*. 1999 Dec 13;446(2):245-253.
59. Pupilli C, **Antonelli A**, Marchetti P, Giannini S, Ferrannini E. Anticorpi anti CD38: un nuovo marker di autoimmunità nel diabete mellito con effetti modulatori sulla secrezione insulinica. *Il Diabete*. 2000; 12: 112-115.
60. Frenzilli G, Bosco E, **Antonelli A**, Panasiuk G, Barale R. DNA damage evaluated by alkaline single cell gel electrophoresis (SCGE) in children of Chernobyl, 10 years after the disaster. *Mutat Res*. 2001 Apr 5;491(1-2):139-149.
61. **Antonelli A**, Baj G, Marchetti P, Fallahi P, Surico N, Pupilli C, Malavasi F, Ferrannini E. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. *Diabetes*. 2001 May;50(5):985-991.
62. **Antonelli A**, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Okamoto H, Ferrannini E. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. *Clin Exp Immunol*. 2001 Dec;126(3):426-431.
63. Ferri C, Zignego AL, Giuggioli D, Sebastiani M, Cazzato M, **Antonelli A**, La Civita L, Fadda P, Longombardo G, Pileri S. HCV and cryoglobulinemic vasculitis. *Cleve Clin J Med*. 2002;69 Suppl 2:SII20-3.
64. **Antonelli A**, Tuomi T, Nannipieri M, Fallahi P, Nesti C, Okamoto H, Groop L, Ferrannini E. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. *Diabetologia*. 2002 Sep;45(9):1298-1306.
65. **Antonelli A**, Ferri C, Fallahi P, Nesti C, Zignego AL, Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. *Clin Exp Rheumatol*. 2002 Sep-Oct;20(5):693-696.
66. Marchetti P, **Antonelli A**, Lupi R, Marselli L, Fallahi P, Nesti C, Baj G, Ferrannini E. Prolonged in vitro exposure to autoantibodies against CD38 impairs the function and survival of human pancreatic islets. *Diabetes*. 2002 Dec;51 Suppl 3:S474-477.
67. Ferri C, Longombardo G, Giuggioli D, Sebastiani M, Cazzato M, La Civita L, Fadda P, **Antonelli A**. Cryoglobulinemia [Le crioglobulinemie] Progressi in Reumatologia. 2002; Suppl 3:45-48.
68. **Antonelli A**, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C, Ferrannini E. Role of neck ultrasonography in the follow-up of children

operated on for thyroid papillary cancer. *Thyroid*. 2003 May;13(5):479-484.

69. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. *Rheumatology (Oxford)*. 2004 Feb;43(2):238-240.

70. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, **Antonelli A**, Puccini R, Michelassi C, Zignego AL. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. *Semin Arthritis Rheum*. 2004 Jun;33(6):355-374.

71. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. *Am J Med*. 2004 Jul 1;117(1):10-13.

72. Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longombardo G, Fadda P, Pampana A, Maccheroni M, Ferrannini E. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. *QJM*. 2004 Aug;97(8):499-506.

73. Spinelli C, Bertocchini A, **Antonelli A**, Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. *J Pediatr Surg*. 2004 Oct;39(10):1500-1505.

74. Antonelli A, Ferrannini E. CD38 autoimmunity: recent advances and relevance to human diabetes. *J Endocrinol Invest*. 2004 Jul-Aug;27(7):695-707.

75. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. *J Clin Endocrinol Metab*. 2004 Nov;89(11):5496-5499.

76. Santini E, Fallahi P, Ferrari SM, Masoni A, **Antonelli A**, Ferrannini E. Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. *Diabetes*. 2004 Dec;53 Suppl 3:S79-83.

77. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. *Eur J Endocrinol*. 2005 Feb;152(2):171-177.

78. Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Baccari GC, Fallahi P, **Antonelli A**, Goglia F. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. *FASEB J*. 2005 Sep;19(11):1552-1554.

79. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Ferrannini E, Serio M. Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. *J Interferon Cytokine Res*. 2005 Sep;25(9):547-552.

80. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C virus infection: evidence for an association with type 2 diabetes. *Diabetes Care*. 2005 Oct;28(10):2548-2550.

81. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Mascia MT, Ferrannini E. Extrahepatic manifestations of hepatitis C virus: the thyroid disorders. *Recenti Prog Med*. 2005 Jul-Aug;96(7-8):370-381.

82. Pupilli C, **Antonelli A**, Iughetti L, D'Annunzio G, Cotellessa M, Vanelli M, Okamoto H, Lorini R, Ferrannini E. Anti-CD38 autoimmunity in children with newly diagnosed type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2005 Dec;18(12):1417-1423.

83. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. *J Clin Endocrinol Metab*. 2006 Feb;91(2):614-620.

84. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. *Clin Endocrinol (Oxf)*. 2006 Feb;64(2):189-195.

85. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. *Eur J Endocrinol*. 2006 May;154(5):651-658.

86. Antonelli A, Rotondi M, Fallahi P, Ferrari SM, Paolicchi A, Romagnani P, Serio M, Ferrannini E. Increase of CXC chemokine CXCL10 and CC

- chemokine CCL2 serum levels in normal ageing. *Cytokine*. 2006 Apr;34(1-2):32-38.
87. Scarpato R, **Antonelli A**, Ballardini M, Cipollini M, Fallahi P, Tomei A, Traino C, Barale R. Analysis of chromosome damage in circulating lymphocytes of radiological workers affected by thyroid nodules. *Mutat Res*. 2006 Jul 14;606(1-2):21-26.
88. **Antonelli A**, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. *Br J Surg*. 2006 Oct;93(10):1226-1231.
89. **Antonelli A**, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, Ferrannini E. Thyroid disorders in chronic hepatitis C virus infection. *Thyroid*. 2006 Jun;16(6):563-572.
90. **Antonelli A**, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. *Chest*. 2006 Aug;130(2):526-532.
91. Galetta F, Franzoni F, Fallahi P, Rossi M, Carpi A, Rubello D, **Antonelli A**, Santoro G. Heart rate variability and QT dispersion in patients with subclinical hypothyroidism. *Biomed Pharmacother*. 2006 Sep;60(8):425-430.
92. Franzoni F, Galetta F, Fallahi P, Tocchini L, Merico G, Braccini L, Rossi M, Carpi A, **Antonelli A**, Santoro G. Effect of L-thyroxine treatment on left ventricular function in subclinical hypothyroidism. *Biomed Pharmacother*. 2006 Sep;60(8):431-436.
93. **Antonelli A**, Delle Sedie A, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. *J Rheumatol*. 2006 Oct;33(10):2026-2028.
94. Rossi M, Galetta F, Franzoni F, **Antonelli A**, Santoro G. Cardiovascular remodelling in patients with sub-clinical hypothyroidism. *Minerva Cardioangiol*. 2006 Dec;54(6):807-810.
95. **Antonelli A**, Ferri C, Fallahi P, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes: Response to Skowronski et al. *Diabetes Care*. 2006 March;29(3):751.
96. **Antonelli A**, Miccoli P, Fallahi P, Ferrari SM, Grosso M, Boni G, Berti P. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. *Surgery*. 2006 Dec;140(6):1035-1041; discussion 1041-1042.
97. Ballardini M, **Antonelli A**, Cipollini M, Fallahi P, Scarpato R, Tomei A, Traino C, Barale R. Induction of chromatid-type aberrations in peripheral lymphocytes of hospital workers exposed to very low doses of radiation. *Mutat Res*. 2007 Jan 10;626(1-2):61-68.
98. Miccoli P, Materazzi G, **Antonelli A**, Panicucci E, Frustaci G, Berti P. New trends in the treatment of undifferentiated carcinomas of the thyroid. *Langenbecks Arch Surg*. 2007 Jul;392(4):397-404.
99. **Antonelli A**, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-{gamma}-Inducible {alpha}-Chemokine CXCL10 Serum Levels in Patients with Active Graves' Disease or Toxic Nodular Goiter. *J Clin Endocrinol Metab*. 2007 Apr;92(4):1485-1490.
100. **Antonelli A**, Ferri C, Fallahi P, Cazzato M, Ferrari SM, Sebastiani M, Ferrannini E. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. *Eur J Endocrinol*. 2007 Apr;156(4):431-437.
101. **Antonelli A**, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, Marchi S, Ferrannini E. Thyroid Cancer in HCV-Related Chronic Hepatitis Patients: A Case-Control Study. *Thyroid*. 2007 May;17(5):447-451.
102. Carpi A, Nicolini A, Marchetti C, Iervasi G, **Antonelli A**, Carpi F. Percutaneous large-needle aspiration biopsy histology of palpable thyroid nodules: technical and diagnostic performance. *Histopathology*. 2007 Aug;51(2):249-257.
103. Ferri C, **Antonelli A**, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Giunti M, Pileri SA, Zignego AL. B-cells and mixed cryoglobulinemia. *Autoimmun Rev*. 2007 Dec;7(2):114-120.
104. Ferri C, **Antonelli A**, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders:

the HCV syndrome. *Dig Liver Dis.* 2007 Sep;39 Suppl 1:S13-21.

105. Galetta F, Franzoni F, Fallahi P, Tocchini L, Braccini L, Santoro G, Antonelli A. Changes in heart rate variability and QT dispersion in patients with overt hypothyroidism. *Eur J Endocrinol.* 2008 Jan;158(1):85-90.

106. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F, Ferrannini E. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study. *Rheumatology (Oxford).* 2008 Jan;47(1):45-49.

107. Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Putini P, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. *Clin Exp Rheumatol.* 2008 Jan-Feb;26(1 Suppl 48):S39-47.

108. Franzoni F, Galetta F, Fallahi P, Tocchini L, Braccini L, Rossi M, Carpi A, Santoro G, Antonelli A. Carotid integrated backscatter analysis in patients with subclinical hypothyroidism. *Clin Endocrinol (Oxf).* 2008 Feb;68(2):278-283.

109. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Ghiadoni L, Serio M, Taddei S, Ferrannini E. High serum levels of CXC chemokine ligand 10 in untreated essential hypertension. *J Hum Hypertens.* 2008 Aug;22(8):579-581.

110. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, Galetta F, Ferrannini E. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. *Cytokine.* 2008 Apr;42(1):137-143.

111. Carpi A, Di Coscio G, Iervasi G, Antonelli A, Mechanick J, Sciacchitano S, Nicolini A. Thyroid fine needle aspiration: How to improve clinicians' confidence and performance with the technique. *Cancer Lett.* 2008 Jun 18;264(2):163-171.

112. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P, Ferrannini E. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. *Eur J Endocrinol.* 2008 Sep;159(3):283-291.

113. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, Marchetti I, Ferrannini E, Miccoli P. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. *Clin Endocrinol (Oxf).* 2008 Jul;69(1):148-152.

114. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Carpi A, Nicolini A, Ferrannini E. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. *Metabolism.* 2008 Sep;57(9):1270-1277.

115. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M, Miccoli P. Dedifferentiated thyroid cancer: A therapeutic challenge. *Biomed Pharmacother.* 2008 Oct;62(8):559-563.

116. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. *Autoimmun Rev.* 2008 Oct;8(1):18-23.

117. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Ferrannini E. Th1 and Th2 Chemokine Serum Levels in Systemic Sclerosis in the Presence or Absence of Autoimmune Thyroiditis. *J Rheumatol.* 2008 Sep;35(9):1809-1811.

118. Antonelli A, Fallahi P, Tolari S, Ferrari SM, Ferrannini E. Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy. *Am J Med Sci.* 2008 Sep;336(3):288-290.

119. Sebastiani M, Manfredi A, Colaci M, Giuggioli D, La Sala R, Elkhaldi N, Antonelli A, Ferri C. [Correlation of a quantitative videocapillaroscopic score with the development of digital skin ulcers in scleroderma patients]. *Reumatismo.* 2008 Jul-Sep;60(3):199-205. Italian.

120. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection. *Am J Gastroenterol.* 2008 Oct;103(10):2488-2494.

121. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in

presence or absence of autoimmune thyroiditis. *Autoimmunity*. 2008 Nov;41(7):537-542.

122. Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d'Annunzio G, Lorini R, Vanelli M, Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. *Diabet Med*. 2008 Nov;25(11):1349-1353.

123. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Ghiri E, Carpi A, Nicolini A, Miccoli P. Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARgamma Agonists? Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2008 Nov;2(3): 194-199.

124. Fallahi P, Ferri C, Ferrari SM, Pampana A, Sansonno D, **Antonelli A**. The emerging extrahepatic manifestations of hepatitis C virus infection in chronic hepatitis and mixed cryoglobulinemia. *Hepatitis Monthly*. 2008; 8(3): 207-211.

125. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Zignego AL, Ferrannini E. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. *Dig Liver Dis*. 2009 Jan;41(1):42-48.

126. Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Grosso M, Boni G, Ferrannini E, Mariani G. Thyroid uptake of (67)Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis. *Eur J Nucl Med Mol Imaging*. 2009 Jan;36(1):137-143.

127. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. *Nat Clin Pract Endocrinol Metab*. 2009 Jan;5(1):26-34.

128. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto M, Giannini R, Marchetti I, Barani L, Basolo F, Ferrannini E, Miccoli P. Thiazolidinediones and antidiabetics in primary human anaplastic thyroid cancer cells. *Clin Endocrinol (Oxf)*. 2009 Jun;70(6):946-953.

129. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Pampana A, Panicucci E, Carpi A, Nicolini A, Ferrannini E. CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. *J Interferon Cytokine Res*. 2009 Jun;29(6):345-51.

130. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthritis. *Clin Exp Rheumatol*. 2009 Jan-Feb;27(1):22-27.

131. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. *J Clin Endocrinol Metab*. 2009 May;94(5):1803-1809.

132. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, **Antonelli A**, Lanni A, Cavaliere G, Barletta A, Goglia F. 3,5-diiodo-L-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. *J Hepatol*. 2009 Aug;51(2):363-370.

133. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Colaci M, Bruschi F, Fallahi P. High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. *Clin Rheumatol*. 2009 Oct;28(10):1179-1185.

134. Scarpato R, Tusa I, **Antonelli A**, Fallahi P, Sbrana I. Spontaneous and bleomycin-induced chromosome damage in non cancer thyroid patients. *Eur J Clin Invest*. 2009 Dec;39(12):1091-1097.

135. Galetta F, Bernini G, Franzoni F, Bacca A, Fivizzani I, Tocchini L, Bernini M, Fallahi P, **Antonelli A**, Santoro G. Cardiac remodeling in patients with primary aldosteronism. *J Endocrinol Invest*. 2009 Oct;32(9):739-745.

136. Miccoli P, Miccoli M, **Antonelli A**, Minuto MN. Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. *Expert Rev Anticancer Ther*. 2009 Sep;9(9):1261-1275.

137. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F, Orlando C, Miccoli P. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. *Endocr Relat Cancer*. 2009 Dec;16(4):1299-1311.

138. Antonelli A, Ferri C, Ferrari SM, Galetta F, Franzoni F, Santoro G, De Marco S, Ghiri E, Fallahi P. High circulating N-terminal pro-brain natriuretic

peptide and tumor necrosis factor- α in mixed cryoglobulinemia. *World J Gastroenterol*. 2009 Oct 28;15(40):5074-5079.

139. Antonelli A, Ferri C, Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN- α therapy. *Nat Rev Gastroenterol Hepatol*. 2009 Nov;6(11):633-635.

140. Carpi A, Nicolini A, **Antonelli A**, Ferrari P, Rossi G. Cytokines in the management of high risk or advanced breast cancer: an update and expectation. *Curr Cancer Drug Targets*. 2009 Dec;9(8):888-903.

141. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Galetta F, Franzoni F, Santoro G, Fallahi P. High circulating levels of N-terminal pro-brain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia. *J Med Virol*. 2010 Feb;82(2):297-303.

142. Antonelli A, Fallahi P, Mosca M, Ferrari SM, Ruffilli I, Corti A, Panicucci E, Neri R, Bombardieri S. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. *Metabolism*. 2010 Jun;59(6):896-900.

143. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sebastiani M, Zignego AL, Ghiri E, Goglia F, Fallahi P. High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. *J Viral Hepat*. 2010 Dec;17(12):851-3.

144. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Goglia F, Pampana A, Bruschi F, Fallahi P. Serum levels of proinflammatory cytokines interleukin-1 β , interleukin-6, and tumor necrosis factor α in mixed cryoglobulinemia. *Arthritis Rheum*. 2009 Dec;60(12):3841-3847.

145. Galetta F, Franzoni F, Cervetti G, Regoli F, Fallahi P, Tocchini L, Carpi A, **Antonelli A**, Petrini M, Santoro G. In vitro and in vivo study on the antioxidant activity of dexrazoxane. *Biomed Pharmacother*. 2010;64(4):259-263.

146. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Sebastiani M, Fallahi P. Serum Concentrations of Interleukin 1 β , CXCL10, and Interferon- γ in Mixed Cryoglobulinemia Associated with Hepatitis C Infection. *J Rheumatol*. 2010 Jan;37(1):91-97.

147. Antonelli A, Mosca M, Fallahi P, Neri R, Ferrari SM, D'Ascanio A, Ghiri E, Carli L, Miccoli P, Bombardieri S. Thyroid Cancer in Systemic Lupus Erythematosus: A Case-Control Study. *J Clin Endocrinol Metab*. 2010 Jan;95(1):314-318.

148. Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Carpi A, **Antonelli A**, Santoro G. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. *Biomed Pharmacother*. 2010 Oct;64(8):516-520.

149. Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, Vitti P, Serio M, Ferrannini E. Interferon- α , - β and - γ induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor- γ agonists. *Cytokine*. 2010 Jun;50(3):260-267.

150. Antonelli A, Ferri C, Ferrari SM, Marchi S, De Bortoli N, Sansonno D, Chiavacci C, Ferrannini E, Fallahi P. N-Terminal Pro-Brain Natriuretic Peptide and Tumor Necrosis Factor- α Both Are Increased in Patients With Hepatitis C. *J Interferon Cytokine Res*. 2010 May;30(5):359-363.

151. Galetta F, Franzoni F, Fallahi P, Tocchini L, Graci F, Gaddeo C, Rossi M, Cini G, Carpi A, Santoro G, **Antonelli A**. Changes in autonomic regulation and ventricular repolarization induced by subclinical hyperthyroidism. *Biomed Pharmacother*. 2010 Oct;64(8):546-549.

152. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, Ruffilli I, Fallahi P. New targeted molecular therapies for dedifferentiated thyroid cancer. *J Oncol*. 2010;2010:921682.

153. Galetta F, Franzoni F, Bernini G, Poupak F, Carpi A, Cini G, Tocchini L, **Antonelli A**, Santoro G. Cardiovascular complications in patients with pheochromocytoma: A mini-review. *Biomed Pharmacother*. 2010 Sep;64(7):505-509.

154. Antonelli A, Ferri C, Ferrari SM, Colaci M, Giuggioli D, Fallahi P. Induction of CXCL10 secretion by interferon- γ and tumour necrosis factor- α and its inhibition by peroxisome proliferator-activated receptor- γ agonists in cultured scleroderma fibroblasts. *Br J Dermatol*. 2010 Sep;163(3):650-1.

155. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, Orlando C, Ferrannini E, Fallahi P. CXCL9 and CXCL11 Chemokines Modulation by Peroxisome Proliferator-Activated Receptor- α Agonists

Secretion in Graves' and Normal Thyrocytes. *J Clin Endocrinol Metab.* 2010 Dec;95(12):E413-20.

156. Antonelli A, Ferri C, Ferrari SM, De Marco S, Di Domenicantonio A, Centanni M, Pupilli C, Villa E, Menichetti F, Fallahi P. Interleukin-1 β , C-X-C Motif Ligand 10, and Interferon-Gamma Serum Levels in Mixed Cryoglobulinemia With or Without Autoimmune Thyroiditis. *J Interferon Cytokine Res.* 2010 Nov;30(11):835-42.

157. Villa E, Karampatou A, Cammà C, Di Leo A, Luongo M, Ferrari A, Petta S, Losi L, Taliani G, Trande P, Lei B, Graziosi A, Bernabucci V, Critelli R, Pазienza P, Rendina M, **Antonelli A**, Francavilla A. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. *Gastroenterology.* 2011 Mar;140(3):818-29.

158. Nicolini A, Ferrari P, Duffy MJ, **Antonelli A**, Rossi G, Metelli MR, Fulceri F, Anselmi L, Conte M, Berti P, Miccoli P. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. *Arch Surg.* 2010 Dec; 145(12):1177-83.

159. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Ali G, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. *J Clin Endocrinol Metab.* 2011 Feb;96(2):E288-96.

160. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Ferrari P, Pupilli C, Nicolini A, Zignego AL, Marchi S, Fallahi P. The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating Interleukin-6, but not of Tumor Necrosis Factor-alpha. *Clin Exp Rheumatol.* 2011 an-Feb;29(1 Suppl 64):S17-22.

161. Antonelli A, Ferrari SM, Fallahi P, Minuto M, Corrado A, Bruno R, Miccoli P. Medullary thyroid cancer: New targeted molecular therapies. 2010 Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 4 (1):10-14.

162. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, Salvi M, Ferrannini E. Cytokines (interferon- γ and tumor necrosis factor- α)-induced nuclear factor- κ B activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. *Metabolism.* 2011 Feb;60(2):277-83.

163. Antonelli A, Ferrari SM, Frascerra S, Corrado A, Pupilli C, Bernini G, Benvenga S, Ferrannini E, Fallahi P. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. *Exp Cell Res.* 2011 Jul 1;317(11):1527-33.

164. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, Ferrannini E, Fallahi P. Increase of Circulating CXCL9 and CXCL11 Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis. *J Clin Endocrinol Metab.* 2011 Jun;96(6):1859-63.

165. Bocci G, Fioravanti A, La Motta C, Orlandi P, Canu B, Di Desidero T, Mugnaini L, Sartini S, Cosconati S, Frati R, **Antonelli A**, Berti P, Miccoli P, Da Settimo F, Danesi R. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. *Biochem Pharmacol.* 2011 Jun 1;81(11):1309-16.

166. Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, **Antonelli A**, Berti P, Carpi A, Miccoli P. Stem cells: their role in breast cancer development and resistance to treatment. *Curr Pharm Biotechnol.* 2011 Feb 1;12(2):196-205.

167. Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, **Antonelli A**, Carpi A, Miccoli P. Cancer stem cells: perspectives of new therapeutical approaches for breast cancer. *Front Biosci (Schol Ed).* 2011 Jun 1;3:1486-99.

168. Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, Miccoli M, Benvenga S, Paolicchi A, Ferrannini E, Fallahi P. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. *Cytokine.* 2011 Aug;55(2):288-93.

169. Antonelli A, Ferri C, Ferrari S, Mancusi C, Colaci M, Sebastiani M, Fallahi P. IFN- γ and TNF- α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. *Scand J Rheumatol.* 2011 Nov;40(6):453-6.

170. Antonelli A, Ferri C, Ferrari SM, Ruffilli I, Colaci M, Frascerra S, Miccoli

M, Franzoni F, Galetta F, Fallahi P. High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon- γ . *J Rheumatol*. 2011 Sep;38(9):1947-52.

171. Antonelli A, Fallahi P, Grosso M, Boni G, Minuto MN, Miccoli P. Lobectomy versus total thyroidectomy in children with post-Chernobyl thyroid cancer: a 15 year follow-up. *Endocrine*. 2011 Dec;40(3):432-6.

172. Antonelli A, Miccoli P, Materazzi G, Minuto M, Fallahi P, Ferrari SM, Berti P. The Role of Total Thyroidectomy in the Initial Treatment of Well-differentiated Follicular-cell-derived Thyroid Carcinomas. *European Endocrinology - Thyroid Disorders*, 2010;6(1):73-6.

173. Antonelli A, Fallahi P, Ulisse S, Ferrari SM, Minuto M, Saraceno G, Santini F, Mazzi V, D'Armiento M, Miccoli P. New Targeted Therapies for Anaplastic Thyroid Cancer. *Anticancer Agents Med Chem*. 2012 Jan 1;12(1):87-93.

174. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Gelmini S, Minuto M, Pupilli C, Miccoli P, Sellari-Franceschini S, Ferrannini E, Fallahi P. Peroxisome proliferator-activated receptor- α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes. *Mol Cell Endocrinol*. 2012 Feb 26;349(2):255-61.

175. Antonelli A, Ferri C, Ferrari SM, Frascerra S, Ruffilli I, Caponi L, Ulisse S, Miccoli M, Miccoli P, Fallahi P. High Levels of Circulating Chemokine (C-X-C motif) Ligand 11 Are Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis and with Chemokine (C-X-C Motif) Ligand 10. *J Interferon Cytokine Res*. 2012 Feb;32(2):74-80.

176. Antonelli A, Fallahi P, Ferrari SM, Sebastiani M, Manfredi A, Mazzi V, Fabiani S, Centanni M, Marchi S, Ferri C. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. *Mod Rheumatol*. 2012 Sep;22(5):659-67. Epub 2011 Dec 14.

177. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. *J Biol Regul Homeost Agents*. 2011 Oct-Dec;25(4):655-60.

178. Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L, Ferri C. RET TKI: Potential Role in Thyroid Cancers. *Curr Oncol Rep*. 2012 Apr;14(2):97-104.

179. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Ali G, Di Desidero T, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. *J Clin Endocrinol Metab*. 2012 Apr;97(4):E528-36.

180. Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, Galleri D, Miccoli P. New targeted therapies for thyroid cancer. *Current Genomics*, 2011; 12:626-631.

181. Nicolini A, Ferrari P, Fallahi P, **Antonelli A**. An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? *Future Oncology*. Feb 2012; 8(2):131-134.

182. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Pupilli C, Bernini G, Sellari Franceschini S, Gelmini S, Ferrannini E, Fallahi P. β (CCL2) and α (CXCL10) chemokines modulation by cytokines and peroxisome proliferator activated receptor- α agonists in Graves' ophthalmopathy. *J Endocrinol*. 2012 May;213(2):183-91.

183. Antonelli A, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Di Domenicantonio A, Ferri C. Systemic Sclerosis Fibroblasts Show Specific Alterations of Interferon- γ and Tumor Necrosis Factor- α -induced Modulation of Interleukin 6 and Chemokine Ligand 2. *J Rheumatol*. 2012 May;39(5):979-85.

184. Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, **Antonelli A**. Cytokines and HCV-Related Disorders. *Clin Dev Immunol*. 2012;2012:468107.

185. Fazzi P, Manni E, Cristofani R, Cei G, Piazza S, Calabrese R, **Antonelli A**, Siciliano G, Barachini P, Carpi A. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. *Biomed and Pharmacother*. June 2012; 66(4):300-307.

186. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, Santarpia L, Basolo F, Ferrannini E, Miccoli P. Variable modulation

by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. *Cytokine*. 2012 Aug;59(2):218-22.

187. Antonelli A, Fallahi P, Ferrari SM, Ghiadoni L, Virdis A, Mancusi C, Centanni M, Taddei S, Ferrannini E. High serum levels of CXC (CXCL10) and CC (CCL2) chemokines in untreated essential hypertension. *Int J Immunopathol Pharmacol*. 2012 Apr-Jun;25(2):387-95.

188. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Mancusi C, Marchi S, De Bortoli N, Metelli MR, Bruschi F, Fallahi P. Hepatitis C is associated with high levels of circulating N-terminal pro-brain natriuretic peptide and interleukin-6. *European Journal of Inflammation*. 2012 Jan-Apr;10(1):133-138.

189. Ferri C, Sebastiani M, **Antonelli A**, Colaci M, Manfredi A, Giuggioli D. Current treatment of hepatitis C-associated rheumatic diseases. *Arthritis Res Ther*. 2012 Jun 25;14(3):215.

190. Antonelli A, Fallahi P, Ferrari SM, Corrado A, Sebastiani M, Manfredi A, Frascerra S, Miccoli M, Zignego AL, Ferrannini E, Ferri C. Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinemia are associated with circulating levels of IFN- γ and TNF- α . *Clin Exp Rheumatol*. 2012 Nov-Dec;30(6):864-70.

191. Antonelli A, Fallahi P, Ferrari SM, Frascerra S, Corrado A, Colaci M, Manfredi A, Maccheroni M, Sansonno D, Zignego AL, Centanni M, Ferri C. Patients with mixed cryoglobulinemia and HCV infection, in presence or absence of autoimmune thyroiditis, have high serum levels of (CXC motif) ligand (CXCL)9 and CXCL11 chemokines. *European Journal of Inflammation*. 2012; 10(3):347-455.

192. Antonelli A, Ferri C, Ferrari SM, Colaci M, Ruffilli I, Sebastiani M, Fallahi P. Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts. *Br J Dermatol*. 2013 Jan;168(1):129-35.

193. Antonelli A, Ferrari SM, Mancusi C, Mazzi V, Pupilli C, Centanni M, Ferri C, Ferrannini E, Fallahi P. Interferon- α , - β and - γ induce CXCL11 secretion in human thyrocytes: Modulation by peroxisome proliferator-activated receptor γ agonists. *Immunobiology*. 2013 May;218(5):690-5.

194. Baldini E, Sorrenti S, D'Armiento E, Guaitoli E, Morrone S, D'Andrea V, Gnessi L, Moretti C, **Antonelli A**, Catania A, De Antoni E, Ulisse S. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. *Clin Ter*. 2012 Sep;163(5):e307-13.

195. Antonelli, A. CXC-Chemokines and Thyroid Associated Autoimmunity. *Journal of Thyroid Disorders & Therapy*, 2012 vol. 01, no. 04.

196. Galetta F, Carpi A, Abraham N, Guidotti E, Russo MA, Camici M, **Antonelli A**, Franzoni F, Santoro G. Age related cardiovascular dysfunction and effects of physical activity. *Front Biosci (Elite Ed)*. 2012 Jun 1;4:2617-37.

197. Cossu A, Ferrannini E, Fallahi P, **Antonelli A**, Sechi LA. Antibodies recognizing specific *Mycobacterium avium* subsp. *paratuberculosis*'s MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. *Cytokine*. 2013 Feb;61(2):337-9.

198. Antonelli A, Fallahi P, Ferrari SM, Frascerra S, Mancusi C, Colaci M, Manfredi A, Sansonno D, Zignego AL, Ferri C. High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. *Int J Immunopathol Pharmacol*. 2013 Jan-Mar;26(1):49-57.

199. Giunti S, **Antonelli A**, Amorosi A, Santarpia L. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. *Int J Endocrinol*. 2013;2013:803171.

200. Baldini E, Sorrenti S, Di Gioia C, De Vito C, **Antonelli A**, Gnessi L, Carbotta G, D'Armiento E, Miccoli P, De Antoni E, Ulisse S. Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology? *BMC Clin Pathol*. 2013 Feb 19;13:7.

201. Antonelli A, Fallahi P, Ferrari SM, Corrado A, Sebastiani M, Giuggioli D, Miccoli M, Zignego AL, Sansonno D, Marchi S, Ferri C. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. *Clin Rheumatol*. 2013 Aug;32(8):1147-54.

202. Carpi A, Cini G, Russo M, **Antonelli A**, Gaudio C, Galetta F, Franzoni F, Rossi G. Subclinical hyperthyroidism and cardiovascular manifestations: a reevaluation of the association. *Intern Emerg Med*. 2013 Apr;8 Suppl 1:S75-7.

203. Bruno RM, Sicari R, Corciu AI, Bianchini E, Faita F, Di Stefano R, **Antonelli A**, Ghiadoni L, Picano E. Non-cancer atherosclerotic effects associated with environmental and therapeutic radiation doses: The Chernobyl thyroid cancer children study. *Int J Cardiol.* 2013 Oct 9;168(4):4255-7.
204. **Antonelli A**, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. Increase of interferon- γ inducible α chemokine (C-X-C motif) ligand (CXCL)9 and CXCL11 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. *Thyroid.* 2013 Nov;23(11):1461-9.
205. **Antonelli A**, Fallahi P, Ferrari SM, Mancusi C, Giuggioli D, Colaci M, Ferri C. Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up. *J Clin Endocrinol Metab.* 2013 Jul;98(7):E1198-202.
206. Giuggioli D, Manfredi A, Colaci M, Manzini CU, **Antonelli A**, Ferri C. Systemic sclerosis and cryoglobulinemia: Our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. *Autoimmun Rev.* 2013 Sep;12(11):1058-63.
207. Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ullisse S, Miccoli P, **Antonelli A**. Sorafenib and Thyroid Cancer. *BioDrugs.* 2013 Dec;27(6):615-28.
208. Vita R, Mazzi V, **Antonelli A**, Benvenaga S. Antithyroid medications and psychosis. *Expert Opin Drug Saf.* 2013 Nov;12(6):865-72.
209. **Antonelli A**, Fallahi P, Ferrari SM, Colaci M, Giuggioli D, Saraceno G, Benvenaga S, Ferri C. Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10. *J Interferon Cytokine Res.* 2013 Dec;33(12):739-45.
210. Ferrari SM, Fallahi P, Mancusi C, Colaci M, Manfredi A, Ferri C, **Antonelli A**. HCV-related autoimmune disorders in HCV chronic infection. *Clin Ter.* 2013 Jul-Aug;164(4):e305-12.
211. Fallahi P, Ferrari SM, Giuggioli D, Corrado A, Fabiani S, Marchi S, Ferri C, **Antonelli A**. Mixed cryoglobulinemia and thyroid autoimmune disorders. *Clin Ter.* 2013 Jul-Aug;164(4):e337-41.
212. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, **Antonelli A**, Gnessi L, Catania A, Moretti C, Mocini R, Carbotta G, Morrone S, Persechino S, Redler A, De Antoni E, D' Armiento M, Ullisse S. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity. *J Biol Regul Homeost Agents.* 2013 Jul-Sep;27(3):705-15.
213. **Antonelli A**, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. *Autoimmun Rev.* 2014 Mar;13(3):272-80.
214. Fallahi P, Ferrari SM, Colaci M, Ruffilli I, Vita R, Azzi A, Ferri C, **Antonelli A**, Ferrannini E. Hepatitis C virus infection and type 2 diabetes. *Clin Ter.* 2013 Sep-Oct;164(5):e393-404.
215. Fallahi P, Di Domenicantonio A, Mazzi V, Santini F, Fabiani S, Sebastiani M, Zignego AL, Ferri C, **Antonelli A**. Hepatitis C virus and type 1 diabetes. *Clin Ter.* 2013 Sep-Oct;164(5):e437-44.
216. **Antonelli A**, Bocci G, Fallahi P, La Motta C, Martina Ferrari S, Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, Piaggi S, Materazzi G, Spinelli C, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. *J Clin Endocrinol Metab.* 2014 Apr;99(4):E572-81.
217. Fallahi P, Ferrari SM, Giuggioli D, Manfredi A, Mancusi C, Fabiani S, Centanni M, Marchi S, Ferri C, **Antonelli A**. Thyroid involvement in hepatitis C - Associated mixed cryoglobulinemia. *Hormones (Athens).* 2014 Jan;13(1):16-23.
218. Sartini S, Coviello V, Bruno A, La Pietra V, Marinelli L, Simorini F, Taliani S, Salerno S, Marini AM, Fioravanti A, Orlandi P, **Antonelli A**, Da Settimo F, Novellino E, Bocci G, La Motta C. Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. *J Med Chem.* 2014 Feb 27;57(4):1225-35.
219. **Antonelli A**, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10 and type 1 diabetes. *Cytokine Growth Factor Rev.* 2014 Feb;25(1):57-65.
220. Martinucci I, de Bortoli N, Savarino E, Piaggi P, Bellini M, **Antonelli A**, Savarino V, Frazzoni M, Marchi S. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. *Neurogastroenterol Motil.* 2014 Apr;26(4):546-555.

221. Fallahi P, Ferrari SM, Mazzi V, Vita R, Benvenga S, **Antonelli A**. Personalization of targeted therapy in advanced thyroid cancer. *Curr Genomics*. 2014 Jun;15(3):190-202.
222. Fallahi P, Giannini R, Miccoli P, **Antonelli A**, Basolo F. Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules. *Curr Genomics*. 2014 Jun;15(3):171-7.
223. **Antonelli A**. "Molecular profiling and ways towards personalized medicine in advanced differentiated thyroid cancer". *Curr Genomics*. 2014 Jun;15(3):161.
224. Ferrari SM, **Antonelli A**, Di Domenicantonio A, Manfredi A, Ferri C, Fallahi P. Modulatory Effects of Peroxisome Proliferator-Activated Receptor- γ on CXCR3 Chemokines. *Recent Pat Inflamm Allergy Drug Discov*. 2014 Jun 23;8(2):132-8.
225. Fallahi P, Ferrari SM, Corrado A, Giuggioli D, Ferri C, **Antonelli A**. Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity. *Recent Pat Endocr Metab Immune Drug Discov*. 2014 Jun 23; 8(2):95-101.
226. **Antonelli A**, Bocci G, La Motta C, Ferrari SM, Fallahi P, Corrado A, Fioravanti A, Sartini S, Orlandi P, Piaggi S, Corti A, Materazzi G, Galleri D, Ulisse S, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. *Mol Cell Endocrinol*. 2014 Jun 12;393(1-2):56-64.
227. Vita R, Fallahi P, **Antonelli A**, Benvenga S. The administration of L-thyroxine as soft gel capsule or liquid solution. *Expert Opin Drug Deliv*. 2014 Jul;11(7):1103-11.
228. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, **Antonelli A**. Thyroid dysfunctions induced by tyrosine kinase inhibitors. *Expert Opin Drug Saf*. 2014 Jun;13(6):723-33.
229. Corrado A, Ferrari SM, Ferri C, Ferrannini E, **Antonelli A**, Fallahi P. Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine. *Clin Ter*. 2014;165(2):e181-5.
230. Mancusi C, Di Domenicantonio A, Politti U, Giuggioli D, **Antonelli A**, Ferri C, Fallahi P. [The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease]. *Clin Ter*. 2014;165(2):e174-80. Italian.
231. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Fallahi P, **Antonelli A**. IP-10 in Autoimmune Thyroiditis. *Horm Metab Res*. 2014 Aug;46(9):597-602.
232. Di Domenicantonio A, Politti U, Giuggioli D, **Antonelli A**, Ferri C, Fallahi P. [The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease and Graves'ophthalmopathy.] *Clin Ter*. 2014 May-Jun;165(3):e230-e236.
233. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Politti U, **Antonelli A**, Fallahi P. [CXCR3 and CXCL10 in autoimmune thyroiditis.] *Clin Ter*. 2014 May-Jun;165(3):e237-e242.
234. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, **Antonelli A**, Gnessi L, Morrone S, Moretti C, Bononi M, Arlot-Bonnemains Y, D'Armiento M, Ulisse S. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. *Endocr Relat Cancer*. 2014 Oct;21(5):797-811.
235. Ferrari SM, Fallahi P, La Motta C, Bocci G, Corrado A, Materazzi G, Galleri D, Piaggi S, Danesi R, Da Settimo F, Miccoli P, **Antonelli A**. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. *Surgery*. 2014 Aug 20. 156(5):1167-1176.
236. Corrado A, Mazzi V, Ferrari SM, Politti U, Giuggioli D, **Antonelli A**, Fallahi P, Ferri C. [Cryoglobulinemia and the α -chemokine IP-10.] *Clin Ter*. 2014 Jul-Aug;165(4):e317-e322.
237. **Antonelli A**, Ferrari SM, Corrado A, Franceschini SS, Gelmini S, Ferrannini E, Fallahi P. Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPAR γ . *Autoimmun Rev*. 2014 Aug 27. 13(11):1160-6.
238. **Antonelli A**, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. *World J Diabetes*. 2014 Oct 15;5(5):586-600.
239. Fallahi P, Ferrari SM, Politti U, Giuggioli D, Ferri C, **Antonelli A**. Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. *Int J Endocrinol*. 2014;2014:935131.

240. **Antonelli A**, Ferrari SM, Ruffilli I, Fallahi P. Cytokines and HCV-related autoimmune disorders. *Immunol Res*. 2014 Dec;60(2-3):311-9.
241. Guidoccio F, Grosso M, **Antonelli A**. Detection of non-Hodgkin lymphoma by [18F]FDG-PET/CT in a patient with differentiated thyroid cancer. *Endocrine*. 2015 Sep;50(1):260-1.
242. **Antonelli A**, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. *Autoimmun Rev*. 2015 Feb;14(2):174-180.
243. Zignego AL, Gragnani L, Piluso A, Sebastiani M, Giuggioli D, Fallahi P, **Antonelli A**, Ferri C. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. *Expert Rev Clin Immunol*. 2015 Jan;11(1):15-31.
244. Fallahi P, Corrado A, Di Domenicantonio A, Frenzilli G, **Antonelli A**, Ferrari SM. CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes. *Curr Drug Targets*. Epub 2014 Dec 29. 2016;17(5):515-9.
245. Mazzi V, Ferrari SM, Giuggioli D, **Antonelli A**, Ferri C, Fallahi P. Role of CXCL10 in cryoglobulinemia. *Clin Exp Rheumatol*. 2015 May-Jun;33(3):433-6.
246. Ferrari SM, Fallahi P, Vita R, **Antonelli A**, Benvenga S. Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity. *PPAR Res*. 2015;2015:232818.
247. Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, Benvenga S, Miccoli P, **Antonelli A**. New Therapies for Dedifferentiated Papillary Thyroid Cancer. *Int J Mol Sci*. 2015 Mar 17;16(3):6153-6182.
248. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, Falvo L, De Vito C, Catania A, Tartaglia F, Mocini R, Cocco C, Alessandrini S, Barollo S, Mian C, **Antonelli A**, De Antoni E, D'Armiento M, Ulisse S. Deregulated expression of aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. *PLoS One*. 2015 Mar 25;10(3):e0121514.
249. Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, **Antonelli A**, Zignego AL. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. *World J Hepatol*. 2015 Mar 27;7(3):327-43.
250. **Antonelli A**, Ferrari SM, Fallahi P. The role of the Th1 chemokine CXCL10 in vitiligo. *Ann Transl Med*. 2015 May;3(Suppl 1):S16.
251. Corrado A, Ferrari SM, Politti U, Mazzi V, Miccoli M, Materazzi G, **Antonelli A**, Ulisse S, Fallahi P, Miccoli P. Aggressive thyroid cancer: targeted therapy with sorafenib. *Minerva Endocrinol*. 2017 Mar;42(1):64-76. Epub 2015 Jun 26.
252. Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, **Antonelli A**. Cabozantinib in Thyroid Cancer. *Recent Pat Anticancer Drug Discov*. 2015;10(3):259-69.
253. Ferrari SM, Politti U, Spisni R, Materazzi G, Baldini E, Ulisse S, Miccoli P, **Antonelli A**, Fallahi P. Sorafenib in the treatment of thyroid cancer. *Expert Rev Anticancer Ther* 2015 Aug;15(8):863-74.
254. Di Domenicantonio A, Politti U, Marchi S, De Bortoli N, Giuggioli D, **Antonelli A**, Ferri C. [A review on thyroid autoimmune disorders and HCV chronic infection]. *Clin Ter*. 2014;165(5):e376-81.
255. Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, **Antonelli A**. Selective use of vandetanib in the treatment of thyroid cancer. *Drug Des Devel Ther*. 2015 Jul 3;9:3459-70.
256. Giuggioli D, Lumetti F, Colaci M, Fallahi P, **Antonelli A**, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. *Autoimmun Rev*. 2015 Nov;14(11):1072-8.
257. Fallahi P, Ferrari SM, Giuggioli D, Sebastiani M, Colaci M, Ferri C, **Antonelli A**. Chemokines in the pathogenesis and as therapeutical markers and targets of HCV chronic infection, and HCV extrahepatic manifestations. *Curr Drug Targets*. 2015 Aug 3. 2017;18:786-793.
258. Ferrari SM, Ruffilli I, Colaci M, **Antonelli A**, Ferri C, Fallahi P. CXCL10 in psoriasis. *Adv Med Sci*. 2015 Aug 12;60(2):349-354.
259. Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, **Antonelli A**. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. *Endocrine*. 2016 Jul;53(1):136-44.
260. Giuggioli D, Sebastiani M, Colaci M, Fallahi P, Gragnani L, Zignego AL, **Antonelli A**, Ferri C. Treatment of HCV-related mixed cryoglobulinemia. *Curr Drug Targets*. 2017;18 (7):794-802
261. Benvenga S, Vita R, Di Bari F, Fallahi P, **Antonelli A**. Do Not Forget

Nephrotic Syndrome as a Cause of Increased Requirement of Levothyroxine Replacement Therapy. *Eur Thyroid J.* 2015 Jun;4(2):138-42.

262. Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Gragnani L, **Antonelli A**, Zignego AL, Ferri C. HCV-related rheumatic manifestations and therapeutic strategies. *Curr Drug Targets.* 2015 Sep 6. 2017;18:803-810.

263. **Antonelli A**, Ferri C, Ferrari SM, Di Domenicantonio A, Giuggioli D, Galleri D, Miccoli P, Fallahi P. Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis. *Rheumatology (Oxford).* 2016 Mar;55(3):480-4.

264. Galetta F, Franzoni F, D'alessandro C, Piazza M, Tocchini L, Fallahi P, **Antonelli A**, Cupisti F, Santoro G. Body composition and cardiac dimensions in elite rhythmic gymnasts. *J Sports Med Phys Fitness.* 2015 Sep;55(9):946-52.

265. Ferrari SM, La Motta C, Sartini S, Baldini E, Materazzi G, Politti U, Ruffilli I, Ulisse S, Miccoli P, **Antonelli A**, Fallahi P. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. *Mini Rev Med Chem.* 2016;16(2):86-93.

266. **Antonelli A**, Pistello M. New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection, and HCV Extrahepatic Manifestations. *Curr Drug Targets.* Epub 2015 Nov 1. 2017;18(7):752-755.

267. Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P, **Antonelli A**. Molecular Targeted Therapies of Aggressive Thyroid Cancer. *Front Endocrinol (Lausanne).* 2015 Nov 20;6:176. eCollection 2015.

268. Fallahi P, Ferrari SM, Giuggioli D, Ferri C, **Antonelli A**. Application of agents against interferon-gamma-dependent chemokines in immunotherapy. *Letters in Drug Design and Discovery.* 2015;12(9):696-703.

269. Fallahi P, Ferrari SM, **Antonelli A**. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. *Endocrine.* 2016;52(3):597-601.

270. Borrelli N, Ugolini C, Giannini R, **Antonelli A**, Giordano M, Sensi E, Torregrossa L, Fallahi P, Miccoli P, Basolo F. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis. *Cancer Cytopathol.* 2016 May;124(5):340-9.

271. Baldini E, Tuccilli C, Prinzi N, Sorrenti S, **Antonelli A**, Fallahi P, Mian C, Barollo S, Catania A, Morrone S, Tartaglia F, Mascagni D, Coccaro C, Pepe M, Filippini A, D'Armiento M, Ulisse S. Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells. *J Biol Regul Homeost Agents.* 2015 Oct-Dec;29(4):793-803.

272. Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, Cantarini L, Bogdanos DP, **Antonelli A**, Amital H, Valesini G, Shoenfeld Y. Smoke and autoimmunity: The fire behind the disease. *Autoimmun Rev.* 2016 Apr;15(4):354-74.

273. Benvenga S, **Antonelli A**, Vita R. Thyroid nodules and thyroid autoimmunity in the context of environmental pollution. *Rev Endocr Metab Disord.* 2015 Dec;16(4):319-40.

274. Ferrari SM, Materazzi G, Baldini E, Ulisse S, Miccoli P, **Antonelli A**, Fallahi P. Antineoplastic Effects of PPAR γ Agonists, with a Special Focus on Thyroid Cancer. *Curr Med Chem.* 2016;23(7):636-49.

275. Fallahi P, Ferrari SM, Elia G, Nasini F, Colaci M, Giuggioli D, Vita R, Benvenga S, Ferri C, **Antonelli A**. Novel Therapies for Thyroid Autoimmune Diseases. *Expert Rev Clin Pharmacol.* 2016 Mar 8:1-9.

276. Vita R, Lapa D, Trimarchi F, Vita G, Fallahi P, **Antonelli A**, Benvenga S. Certain HLA alleles are associated with stress-triggered Graves' disease and influence its course. *Endocrine.* 2017 Jan;55(1):93-100.

277. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Giuggioli D, Colaci M, Ferri C, **Antonelli A**. Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. *Autoimmun Rev.* 2016 Jul;15(7):747-51.

278. Fallahi P, Ferrari SM, Ruffilli I, **Antonelli A**. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. *BMC Gastroenterol.* 2016 Feb 24;16(1):22.

279. Fallahi P, Ferrari SM, Vita R, Benvenga S, **Antonelli A**. The role of human parvovirus B19 and hepatitis C virus in the development of thyroid disorders. *Rev Endocr Metab Disord.* 2016 Dec;17(4):529-535.

280. Fallahi P, Ferrari SM, Camastra S, Politti U, Ruffilli I, Vita R, Navarra G,

- Benvenga S, **Antonelli A**. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation. *Obes Surg*. 2017 Jan;27(1):78-82.
- 281.** Benvenga S, **Antonelli A**. Inositol(s) in thyroid function, growth and autoimmunity. *Rev Endocr Metab Disord*. 2016 Dec;17(4):471-484.
- 282.** Fallahi P, Ferrari SM, Ruffilli I, Ragusa F, Biricotti M, Materazzi G, Miccoli P, **Antonelli A**. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update. *Expert Opin Drug Deliv*. 2017 May;14(5):647-655.
- 283.** Fallahi P, Ferrari SM, Marchi S, De Bortoli N, Ruffilli I, **Antonelli A**. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. *Endocrine*. 2017 Jul;57(1):175-178.
- 284.** Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R, Benvenga S, **Antonelli A**. The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. *Autoimmun Rev*. 2016;15(12):1125-1128.
- 285.** Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, **Antonelli A**, Saadoun D, Desbois AC, Sebastiani M, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV coauthors. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. *Autoimmun Rev*. 2016 Dec;15(12):1145-1160.
- 286.** Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, **Antonelli A**. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. *Expert Rev Anticancer Ther*. 2016 Nov;16(11):1109-1118.
- 287.** Fallahi P, Ferrari SM, **Antonelli A**. In patients with subclinical hypothyroidism while in therapy with tablet l-t4, the liquid l-t4 formulation is more effective in restoring euthyroidism. *Endocr Pract*. 2017 Feb;23(2):170-174.
- 288.** Giuggioli D, Colaci M, Cassone G, Fallahi P, Lumetti F, Spinella A, Campomori F, Manfredi A, Manzini CU, **Antonelli A**, Ferri C. Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. *Clin Rheumatol*. 2017 Mar;36(3):583-590.
- 289.** Baldini E, Tuccilli C, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, Catania A, D'Armiento E, **Antonelli A**, Fallahi P, Watutantrige-Fernando S, Tartaglia F, Barollo S, Mian C, Bononi M, Arceri S, Mascagni D, Vergine M, Pironi D, Monti M, Filippini A, Ulisse S. Deregulated expression of VHL mRNA variants in papillary thyroid cancer. *Mol Cell Endocrinol*. 2017 Mar 5;443:121-127.
- 290.** Fallahi P, Ferrari SM, Ruffilli I, Elia G, Miccoli M, Sedie AD, Riente L, **Antonelli A**. Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. *Immunol Res*. 2017 Jun;65(3):681-686.
- 291.** Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, **Antonelli A**, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. *Autoimmun Rev*. 2017 May;16(5):523-541.
- 292.** Tuccilli C, Baldini E, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, D'Armiento E, **Antonelli A**, Fallahi P, Watutantrige S, Tartaglia F, Barollo S, Mian C, Arceri S, Mascagni D, Pironi D, Bononi M, Vergine M, Monti M, Filippini A, Ulisse S. Expression and prognostic value of the cell polarity PAR complex members in thyroid cancer. *Int J Oncol*. 2017 Mar 8;50(4):1413-1422. doi: 10.3892/ijo.2017.3907.
- 293.** Ferrari SM, Fallahi P, **Antonelli A**, Benvenga S. Environmental Issues in Thyroid Diseases. *Front Endocrinol (Lausanne)*. 2017;8:50. doi: 10.3389/fendo.2017.00050. eCollection 2017.
- 294.** **Antonelli A**, Fallahi P, Di Bari F, Giuggioli D, Ferrari SM, Ferri C. Fatigue in patients with systemic sclerosis and hypothyroidism. A review of the literature and report of our experience. *Clin Exp Rheumatol*. 2017 Sep-Oct;35 Suppl 106(4):193-197.
- 295.** Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, **Antonelli A**, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. *N Engl J Med*. 2017

May 4;376(18):1748-1761.

296. Le Donne M, Mento C, Settineri S, **Antonelli A**, Benvenga S. Postpartum Mood Disorders and Thyroid Autoimmunity. *Front Endocrinol (Lausanne)*. 2017 May 4;8:91. doi: 10.3389/fendo.2017.00091. eCollection 2017.

297. Antonelli A, La Motta C. Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells. *Med Res Rev*. 2017 Nov;37(6):1299-1317.

298. Ferrari SM, Elia G, Virili C, Centanni M, **Antonelli A**, Fallahi P. Systemic Lupus Erythematosus and Thyroid Autoimmunity. *Front Endocrinol (Lausanne)*. 2017 Jun 19;8:138.

299. Ruffilli I, Ragusa F, Benvenga S, Vita R, **Antonelli A**, Fallahi P, Ferrari SM. Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity. *Front Endocrinol (Lausanne)*. 2017 Jun 19;8:139. doi: 10.3389/fendo.2017.00139. eCollection 2017.

300. Spinelli C, Rossi L, Piscioneri J, Strambi S, **Antonelli A**, Ferrari A, Massimino M, Miccoli P. Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery. *Curr Pediatr Rev*. 2016;12(4):247-252.

301. Ferrari SM, Fallahi P, Santaguida G, Virili C, Ruffilli I, Ragusa F, Centanni M, **Antonelli A**. Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. *Autoimmun Rev*. 2017 Sep;16(9):946-950.

302. Benvenga S, Vicchio T, Di Bari F, Vita R, Fallahi P, Ferrari SM, Catania S, Costa C, **Antonelli A**. Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with Hashimoto's thyroiditis: preliminary in vitro studies. *Eur Rev Med Pharmacol Sci*. 2017 Jun;21(2 Suppl):89-101.

303. Ferrari SM, Fallahi P, Di Bari F, Vita R, Benvenga S, **Antonelli A**. Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis. *Eur Rev Med Pharmacol Sci*. 2017 Jun;21(2 Suppl):36-42.

304. Ferrari SM, Elia G, Piaggi S, Baldini E, Ulisse S, Miccoli M, Materazzi G, **Antonelli A**, Fallahi P. CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer. *Anticancer Agents Med Chem*. 2018;18(3):458-466.

305. Ferri C, Colaci M, Fallahi P, Ferrari SM, **Antonelli A**, Giuggioli D. Thyroid Involvement in Hepatitis C Virus-Infected Patients with/without Mixed Cryoglobulinemia. *Front Endocrinol (Lausanne)*. 2017 Jul 7;8:159. doi: 10.3389/fendo.2017.00159. eCollection 2017.

306. Fallahi P, Ferrari SM, Santini E, Camastra S, Frenzilli G, Puccini M, Goglia F, Lanni A, Marchetti P, **Antonelli A**. Both 3,5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion. *J Biol Regul Homeost Agents*. 2017 Apr-Jun;31(2):503-508.

307. Benvenga S, Papi G, **Antonelli A**. Refractory Hypothyroidism Due to Improper Storage of Levothyroxine Tablets. *Front Endocrinol (Lausanne)*. 2017 Jul 10;8:155. doi: 10.3389/fendo.2017.00155. eCollection 2017.

308. Di Desidero T, **Antonelli A**, Orlandi P, Ferrari SM, Fioravanti A, Ali G, Fontanini G, Basolo F, Francia G, Bocci G. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. *Cancer Lett*. 2017 Sep 28;411:35-43.

309. Lamartina L, Durante C, Lucisano G, Grani G, Bellantone RA, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, **Antonelli A**, Limone PP, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Mian C, Spiazzi G, Persani L, Barbaro D, Nicolucci A, Filetti S. Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory (ITCO#1). *Thyroid*. 2017 Dec;27(12):1490-1497

310. Benvenga S, Di Bari F, Granese R, **Antonelli A**. Serum Thyrotropin and Phase of the Menstrual Cycle. *Front Endocrinol (Lausanne)*. 2017 Sep 29;8:250. doi: 10.3389/fendo.2017.00250. eCollection 2017.

311. Fallahi P, Ruffilli I, Giuggioli D, Colaci M, Ferrari SM, **Antonelli A**, Ferri C. Associations between Systemic Sclerosis and Thyroid Diseases. *Front Endocrinol (Lausanne)*. 2017 Oct 3;8:266. doi: 10.3389/fendo.2017.00266.

eCollection 2017.

- 312.** Fallahi P, Foddìs R, Cristaudo A, **Antonelli A**. High risk of brain tumors in farmers: a mini-review of the literature, and report of the results of a case control study. *Clin Ter*. 2017 Sep-Oct;168(5):e290-e292.
- 313.** Fallahi P, Ruffilli I, Elia G, Ragusa F, Ulisse S, Baldini E, Miccoli M, Materazzi G, **Antonelli A**, Ferrari SM. Novel treatment options for anaplastic thyroid cancer. *Expert Rev Endocrinol Metab*. 2017; 12(4):279-288.
- 314.** Ferrari SM, Centanni M, Virili C, Miccoli M, Ferrari P, Ruffilli I, Ragusa F, **Antonelli A**, Fallahi P. Sunitinib in the treatment of thyroid cancer. *Curr Med Chem*. 2017 Oct 6. doi: 10.2174/0929867324666171006165942.
- 315.** **Antonelli A**, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid cancer. *Expert Rev Anticancer Ther*. 2018 Feb;18(2):149-159.
- 316.** Fallahi P, Elia G, Foddìs R, Cristaudo A, **Antonelli A**. High risk of brain tumors in military personnel: a case control study. *Clin Ter*. 2017 Nov-Dec;168(6):e376-e379.
- 317.** Santaguida MG, Gatto I, Mangino G, Virili C, Stramazzo I, Fallahi P, **Antonelli A**, Segni M, Romeo G, Centanni M. BREG cells in Hashimoto's thyroiditis isolated or associated to further organ-specific autoimmune diseases. *Clin Immunol*. 2017 Nov;184:42-47.
- 318.** Pandiyan B, Merrill SJ, Bari FD, **Antonelli A**, Benvenga S. A patient-specific treatment model for Graves' hyperthyroidism. *Theor Biol Med Model*. 2018 Jan 9;15(1):1.
- 319.** Fabiani S, Fallahi P, Ferrari SM, Miccoli M, **Antonelli A**. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. *Rev Endocr Metab Disord*. 2018 Jan 11. doi: 10.1007/s11154-017-9440-1.
- 320.** Virili C, Giovanella L, Fallahi P, **Antonelli A**, Santaguida MG, Centanni M, Trimboli P. Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. *Front Endocrinol (Lausanne)*. 2018 Jan 26;9:10.
- 321.** Ferrari SM, Ruffilli I, Centanni M, Virili C, Materazzi G, Alexopoulou M, Miccoli M, **Antonelli A**, Fallahi P. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. *Recent Pat Anticancer Drug Discov*. 2018;13(2):201-208.
- 322.** Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, **Antonelli A**, Fallahi P. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. *Oncol Rep*. 2018 May;39(5):2225-2234. doi: 10.3892/or.2018.6306.
- 323.** Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, Elia G, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, **Antonelli A**, Fallahi P. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. *Oncol Rep*. 2018 May;39(5):2306-2314. doi: 10.3892/or.2018.6305.
- 324.** Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Benvenga S, Cristaudo A, **Antonelli A**, Ferrari SM. Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells. *Oncol Rep*. 2018 May;39(5):2422-2426 doi: 10.3892/or.2018.6307.
- 325.** Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Guglielmi G, Frenzilli G, Benvenga S, Cristaudo A, **Antonelli A**, Ferrari SM. Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide. *Mol Med Rep*. 2018 17:6914-6918. doi: 10.3892/mmr.2018.8712.
- 326.** La Pietra V, Sartini S, Botta L, **Antonelli A**, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. *Eur J Med Chem*. *Eur J Med Chem*. 2018 Mar 2;150:491-505. doi: 10.1016/j.ejmech.2018.02.080.
- 327.** Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Frenzilli G, Benvenga S, Cristaudo A, **Antonelli A**, Ferrari SM. Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells. *Mol Med Rep*. 2018 17:7415-7420.
- 328.** Baldini C, Ferro F, Mosca M, Fallahi P, **Antonelli A**. The Association of Sjögren Syndrome and Autoimmune Thyroid Disorders. *Front Endocrinol (Lausanne)*. 2018 Apr 3;9:121. doi: 10.3389/fendo.2018.00121. eCollection 2018.
- 329.** Benvenga S, Capodicasa G, Perelli S, Ferrari SM, Fallahi P, **Antonelli**

- A.** Increased Requirement of Replacement Doses of Levothyroxine Caused by Liver Cirrhosis. *Front Endocrinol (Lausanne)*. 2018 Apr 18;9:150. doi: 10.3389/fendo.2018.00150. eCollection 2018.
- 330.** Benvenga S, Di Bari F, Granese R, Borrielli I, Giorgianni G, Grasso L, Le Donne M, Vita R, **Antonelli A**. Circulating thyrotropin is upregulated by estradiol. *J Clin Transl Endocrinol*. 2018 Feb 13;11:11-17. doi: 10.1016/j.jcte.2018.02.002.
- 331.** Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Benvenga S, Cristaudo A, **Antonelli A**, Ferrari SM. CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide. *Mol Med Rep*. 2018 Aug;18(2):1798-1803.
- 332.** Tuccilli C, Baldini E, Sorrenti S, Catania A, **Antonelli A**, Fallahi P, Tartaglia F, Barollo S, Mian C, Palmieri A, Carbotta G, Arcieri S, Pironi D, Vergine M, Monti M, Ulisse S. CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. *Int J Endocrinol*. 2018 Jul 5;2018:1742951. doi: 10.1155/2018/1742951. eCollection 2018.
- 333.** Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR, Ulisse S, Baldini E, Giannini R, Miccoli P, **Antonelli A**, Basolo F. Molecular testing in the diagnosis of differentiated thyroid carcinomas. *Gland Surg*. 2018 Aug;7(Suppl 1):S19-S29. doi: 10.21037/gs.2017.11.07.
- 334.** Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, **Antonelli A**. Thyroid disorders induced by checkpoint inhibitors. *Rev Endocr Metab Disord*. 2018 Sep 21. doi: 10.1007/s11154-018-9463-2.
- 335.** **Antonelli A**, Benvenga S. Editorial: The Association of Other Autoimmune Diseases in Patients With Thyroid Autoimmunity. *Front Endocrinol (Lausanne)*. 2018 Sep 13;9:540. doi: 10.3389/fendo.2018.00540. eCollection 2018.
- 336.** Virili C, Fallahi P, **Antonelli A**, Benvenga S, Centanni M. Gut microbiota and Hashimoto's thyroiditis. *Rev Endocr Metab Disord*. 2018 Oct 8. doi: 10.1007/s11154-018-9467-y.
- 337.** Santaguida MG, Gatto I, Mangino G, Virili C, Stramazzo I, Fallahi P, **Antonelli A**, Gargiulo P, Romeo G, Centanni M. Breg Cells in Celiac Disease Isolated or Associated to Hashimoto's Thyroiditis. *Int J Endocrinol*. 2018 Oct 8;2018:5290865. doi: 10.1155/2018/5290865. eCollection 2018.
- 338.** Fallahi P, Ferrari SM, Materazzi G, Ragusa F, Ruffilli I, Patrizio A, Miccoli P, **Antonelli A**. Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study. *Laryngoscope Investig Otolaryngol*. 2018 Oct 3;3(5):405-408. doi: 10.1002/lio2.186. eCollection 2018.
- 339.** Virili C, **Antonelli A**, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal Malabsorption of Thyroxine. *Endocr Rev*. 2019 Feb 1;40(1):118-136. doi: 10.1210/er.2018-00168.
- 340.** Colaci M, Malatino L, **Antonelli A**, Fallahi P, Giuggioli D, Ferri C. Endocrine disorders associated with hepatitis C virus chronic infection. *Rev Endocr Metab Disord*. 2018 Dec;19(4):397-403. doi: 10.1007/s11154-018-9475-y.
- 341.** Ferrari SM, Elia G, Ragusa F, Paparo SR, Caruso C, Benvenga S, Fallahi P, **Antonelli A**. The protective effect of myo-inositol on human thyrocytes. *Rev Endocr Metab Disord*. 2018 Dec;19(4):355-362. doi: 10.1007/s11154-018-9476-x.
- 342.** Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Caruso C, Guglielmi G, **Antonelli A**. Myo-inositol in autoimmune thyroiditis, and hypothyroidism. *Rev Endocr Metab Disord*. 2018 Dec;19(4):349-354. doi: 10.1007/s11154-018-9477-9.
- 343.** Fallahi P, Ferrari SM, Piaggi S, Luconi M, Cantini G, Gelmini S, Elia G, Ruffilli I, **Antonelli A**. The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results. *Immunol Res*. 2019 Jan 8. doi: 10.1007/s12026-018-9056-x. [Epub ahead of print]
- 344.** Ferrari SM, La Motta C, Elia G, Ragusa F, Ruffilli I, Quattrini L, Paparo SR, Piaggi S, Patrizio A, Ulisse S, Baldini E, Materazzi G, Fallahi P, **Antonelli A**. Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. *Front Endocrinol (Lausanne)*. 2018 Dec 18;9:764. doi: 10.3389/fendo.2018.00764.
- 345.** Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, **Antonelli A**. The association of other autoimmune diseases in patients with Graves'

- disease (with or without ophthalmopathy): Review of the literature and report of a large series. *Autoimmun Rev.* 2019 Mar;18(3):287-292. doi: 10.1016/j.autrev.2018.10.001.
- 346.** Koch CA, **Antonelli A.** Immunoendocrinology: When (neuro)endocrinology and immunology meet. *Rev Endocr Metab Disord.* 2018 Dec;19(4):277-282. doi: 10.1007/s11154-018-9479-7.
- 347.** Ulisse S, Tuccilli C, Sorrenti S, **Antonelli A**, Fallahi P, D'Armiento E, Catania A, Tartaglia F, Amabile MI, Giacomelli L, Metere A, Cornacchini N, Pironi D, Carbotta G, Vergine M, Monti M, Baldini E. PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. *Int J Mol Sci.* 2019 Mar 20;20(6).
- 348.** Ferrari SM, Ragusa F, Paparo SR, Nasini F, Nardi M, Franceschini SS, Fallahi P, **Antonelli A.** Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy. *Autoimmun Rev.* 2019 Jul;18(7):673-678.
- 349.** Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Patrizio A, Galdiero MR, Baldini E, Ulisse S, Marone G, **Antonelli A.** Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. *Int J Mol Sci.* 2019 May 24;20(10). pii: E2560.
- 350.** Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Paparo SR, **Antonelli A.** Thyroid autoimmune disorders and cancer. *Semin Cancer Biol.* 2019 May 31. pii: S1044-579X(18)30159-7.
- 351.** Ferrari SM, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, **Antonelli A**, Fallahi P. Chemokines in hyperthyroidism. *J Clin Transl Endocrinol.* 2019 May 17;16:100196.
- 352.** **Antonelli A**, Ferrari SM, Elia G, Patrizio A, Fallahi P. Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. *Gland Surg.* 2019;8(3):298-300.
- 353.** Ferrari SM, Fallahi P, La Motta, C, Elia G, Ragusa, F, Ruffilli I, Patrizio A, Baldini E, Ulisse, S, **Antonelli A.** Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. *Expert Rev Precision Med Drug Develop.* 2019;4(1):37-49.
- 354.** Pallio G, Micali A, Benvenga S, **Antonelli A**, Marini HR, Puzzolo D, Macaione V, Trichilo V, Santoro G, Irrera N, Squadrito F, Altavilla D, Minutoli L. Myo-inositol in the protection from cadmium-induced toxicity in mice kidney: An emerging nutraceutical challenge. *Food Chem Toxicol.* 2019 Oct;132:110675.
- 355.** Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM, de Paulis A, **Antonelli A**, Galdiero MR. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. *Int J Mol Sci.* 2019 Aug 13;20(16). pii: E3934.
- 356.** Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Colaci M, Giuggioli D, Ferri C, **Antonelli A.** Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C? *J Immunol Res.* 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960
- 357.** Ferrari SM, **Antonelli A**, Guidi P, Bernardeschi M, Scarcelli V, Fallahi P, Frenzilli G. Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy. *Nutr Cancer.* 2019 Apr 24:1-10. doi: 10.1080/01635581.2019.1604004.
- 358.** Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Varricchi G, Marone G, **Antonelli A.** Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. *Int J Mol Sci.* 2019 Sep 7;20(18). pii: E4413. doi: 10.3390/ijms20184413. Review.
- 359.** Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Materazzi G, **Antonelli A.** Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes. *Cancer Manag Res.* 2019 Aug 21;11:7893-7907. doi: 10.2147/CMAR.S127848. eCollection 2019.
- 360.** Ragusa F, Fallahi P, Elia G, Gonnella D, Paparo SR, Giusti C, Churilov LP, Ferrari SM, **Antonelli A.** Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy. *Best Pract Res Clin Endocrinol Metab.* 2019 Nov 26:101367. doi: 10.1016/j.beem.2019.101367. [Epub ahead of print].
- 361.** Ferrari SM, Fallahi P, Elia G, Ragusa F, Camastra S, Paparo SR, Giusti C, Gonnella D, Ruffilli I, Shoenfeld Y, **Antonelli A.** Novel therapies for thyroid autoimmune diseases: An update. *Best Pract Res Clin Endocrinol Metab.* 2019 Nov 28:101366. doi: 10.1016/j.beem.2019.101366. [Epub ahead of print].

362. Fallahi P, Ferrari SM, Ragusa F, Ruffilli I, Elia G, Paparo SR, **Antonelli A**. Th1 Chemokines in Autoimmune Endocrine Disorders. *J Clin Endocrinol Metab*. 2020 Apr 1;105(4):dgz289. doi: 10.1210/clinem/dgz289.
363. Cellini M, Santaguida MG, Stramazzo I, Capriello S, Brusca N, **Antonelli A**, Fallahi P, Gargano L, Centanni M, Virili C. Recurrent Pregnancy Loss in Women with Hashimoto's Thyroiditis with Concurrent Non-Endocrine Autoimmune Disorders. *Thyroid*. 2020 Mar;30(3):457-462. doi: 10.1089/thy.2019.0456.
364. Fallahi P, Elia G, Ragusa F, Ruffilli I, Camastra S, Giusti C, Paparo SR, Gonnella D, Shoenfeld Y, Ferrari SM, **Antonelli A**. The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases. *Best Pract Res Clin Endocrinol Metab*. 2019 Dec;33(6):101372. doi: 10.1016/j.beem.2019.101372.
365. **Antonelli A**, Shoenfeld Y. Autoimmunity and the endocrine system: Thyroid, hypophysis and pregnancy. *Best Pract Res Clin Endocrinol Metab*. 2019 Dec;33(6):101374. doi: 10.1016/j.beem.2020.101374.
366. Cristinziano L, Modestino L, Loffredo S, Varricchi G, Braile M, Ferrara AL, de Paulis A, **Antonelli A**, Marone G, Galdiero MR. Anaplastic Thyroid Cancer Cells Induce the Release of Mitochondrial Extracellular DNA Traps by Viable Neutrophils. *J Immunol*. 2020 Mar 1;204(5):1362-1372. doi: 10.4049/jimmunol.1900543.
367. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EH, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, **Antonelli A**, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the Treatment of Active Thyroid Eye Disease. *N Engl J Med*. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.
368. Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, Varricchi G, Fallahi P, **Antonelli A**. New insight in endocrine-related adverse events associated to immune checkpoint blockade. *Best Pract Res Clin Endocrinol Metab*. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370.
369. Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, **Antonelli A**. Novel treatments for anaplastic thyroid carcinoma. *Gland Surg*. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18.
370. **Antonelli A**, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C, Centanni M, Shoenfeld Y, Ferrari SM. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. *Best Pract Res Clin Endocrinol Metab*. 2020 Jan;34(1):101388. doi: 10.1016/j.beem.2020.101388.
371. Benvenga S, Elia G, Ragusa F, Paparo SR, Sturniolo MM, Ferrari SM, **Antonelli A**, Fallahi P. Endocrine disruptors and thyroid autoimmunity. *Best Pract Res Clin Endocrinol Metab*. 2020 Jan;34(1):101377. doi: 10.1016/j.beem.2020.101377.
372. **Antonelli A**, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, Patrizio A, Giusti C, Gonnella D, Cristaudo A, Foddìs R, Shoenfeld Y, Fallahi P. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. *Best Pract Res Clin Endocrinol Metab*. 2020 Jan;34(1):101387. doi: 10.1016/j.beem.2020.101387.
373. **Antonelli A**, Shoenfeld Y. Autoimmunity and the endocrine system: Adrenal, Graves' disease, immune checkpoint. *Best Pract Res Clin Endocrinol Metab*. 2020 Jan;34(1):101413. doi: 10.1016/j.beem.2020.101413.
374. Benvenga S, Marini HR, Micali A, Freni J, Pallio G, Irrera N, Squadrito F, Altavilla D, **Antonelli A**, Ferrari SM, Fallahi P, Puzzolo D, Minutoli L. Protective Effects of Myo-Inositol and Selenium on Cadmium-Induced Thyroid Toxicity in Mice. *Nutrients*. 2020 Apr 26;12(5):1222. doi: 10.3390/nu12051222.
375. Benvenga S, Ferrari SM, Elia G, Ragusa F, Patrizio A, Paparo SR, Camastra S, Bonofiglio D, **Antonelli A**, Fallahi P. Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies. *Nutrients*. 2020 May 8;12(5):1337. doi: 10.3390/nu12051337.
376. Muzzio ML, Kabakian ML, Morosán-Allo Y, Ferrari S, Fallahi P, Fernández J, Santucci MP, Andrés-Lacueva C, **Antonelli A**, Brenta G, Meroño T. Association of glomerular hyperfiltration with serum chemokine levels and metabolic features in prepubertal children with overweight/obesity. *Nutr Metab Cardiovasc Dis*. 2020 Jun 25;30(7):1188-1195. doi: 10.1016/j.numecd.2020.03.012.
377. Grani G, Zatelli MC, Alfò M, Montesano T, Torlontano M, Morelli S,

Deandrea M, **Antonelli A**, Francese C, Ceresini G, Orlandi F, Maniglia CA, Bruno R, Monti S, Santaguida MG, Repaci A, Tallini G, Fugazzola L, Monzani F, Giubbini R, Rossetto R, Mian C, Crescenzi A, Tumino D, Pagano L, Pezzullo L, Lombardi CP, Arvat E, Petrone L, Castagna MG, Spiazzi G, Salvatore D, Meringolo D, Solaroli E, Monari F, Magri F, Triggiani V, Castello R, Piazza C, Rossi R, Ferraro Petrillo U, Filetti S, Durante C. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. *Thyroid*. 2020 Jul 1. doi: 10.1089/thy.2020.0272. [Epub ahead of print].

378. Fallahi P, Ferrari SM, Elia G, Ragusa F, Patrizio A, Paparo SR, Marone G, Galdiero MR, Guglielmi G, Foddìs R, Cristaudo A, **Antonelli A**. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. *Semin Cancer Biol*. 2022 Feb;79:203-216. doi: 10.1016/j.semcancer.2020.06.013.

379. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, Guiducci S, Ursini F, Caminiti M, Varcasia G, Gigliotti P, Pellegrini R, Olivo D, Colaci M, Murdaca G, Brittelli R, Mariano GP, Spinella A, Bellando-Randone S, Aiello V, Bilia S, Giannini D, Ferrari T, Caminiti R, Brusi V, Meliconi R, Fallahi P, **Antonelli A**; COVID-19 & ASD Italian Study Group. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. *Clin Rheumatol*. 2020 Aug 27:1–10. doi: 10.1007/s10067-020-05334-7. [Epub ahead of print].

380. Borodina E, Katz I, **Antonelli A**, Gzgzyan AM, Dzhemlikhanova LK, Ostrinski Y, Niauri D, Khizroeva J, Bitsadze V, Makatsariya A, Tincani A, Nalli C, Churilov LP, Shovman O, Halpert G, Blank M, Shoenfeld Y, Amital H. The pathogenic role of circulating Hashimoto's Thyroiditis-derived TPO-positive IgG on fetal loss in naïve mice. *Am J Reprod Immunol*. 2020 Sep 6:e13331. doi: 10.1111/aji.13331. [Epub ahead of print].

381. Ferri C, Giuggioli D, Raimondo V, Fallahi P, Antonelli A; COVID-19 & ASD Italian Study Group. COVID-19 in Italian patients with rheumatic autoimmune systemic diseases. *Ann Rheum Dis* 2023 Sep;82(9):e211. doi: 10.1136/annrheumdis-2020-219113.

382. **Antonelli A**, Elia G, Ferrari SM, Foddìs R, De Marco S, Cristaudo A, Fallahi P. The Covid-19, Epidemiology, Clinic and Prevention. *Curr Genomics*. 2020 Apr;21(3):157. doi: 10.2174/1389202921999200427133052.

383. Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Camastra S, Mazzi V, Miccoli M, Benvenga S, **Antonelli A**. THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors. *Eur J Endocrinol*. 2020 Oct 1:EJE-20-0683.R2. doi: 10.1530/EJE-20-0683. [Epub ahead of print].

384. Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, **Antonelli A**. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. *Semin Cancer Biol*. 2022 Feb;79:180-196. doi: 10.1016/j.semcancer.2020.11.013.

385. Sorrenti S, Carbotta G, Di Matteo FM, Catania A, Pironi D, Tartaglia F, Tarroni D, Gagliardi F, Tripodi D, Watanabe M, Mariani S, D'Armiento E, Fallahi P, Sindoni A, De Vito C, **Antonelli A**, Ullisse S, Baldini E. Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study. *Cancers (Basel)*. 2020 Dec 4;12(12):3637. doi: 10.3390/cancers12123637.

386. **Antonelli A**, Ferrari SM, Fallahi P. Slit2 regulation of hyaluronan & cytokine synthesis in fibrocytes in thyroid associated ophthalmopathy. *J Clin Endocrinol Metab*. 2020 Dec 24:dga959. doi: 10.1210/clinem/dga959. Online ahead of print. mancano codice scopus isi caricato PDF in press

387. Ferri C, Giuggioli D, Raimondo V, Dagna L, Ricciari V, Zanatta E, Guiducci S, Tavoni A, Foti R, Cuomo G, De Angelis R, Cozzi F, Murdaca G, Cavazzana I, Romeo N, Codullo V, Ingegnoli F, Pellegrini R, Varcasia G, Rossa AD, De Santis M, Abignano G, Colaci M, Caminiti M, L'Andolina M, Lubrano E, Spinella A, Lumetti F, De Luca G, Bellando-Randone S, Visalli E, Bilia S, Giannini D, Masini F, Pellegrino G, Pigatto E, Generali E, Dall'Ara F, Mariano GP, Barsotti S, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Scorpiniti D, Ferrari T, Caminiti R, Campochiaro C, D'Angelo S, Iannone F, Matucci-Cerinic M, Doria A, Miccoli M, Fallahi P, **Antonelli A**; COVID-19 & Autoimmune Systemic Diseases Italian Study Group. COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. *Lancet Rheumatol*. 2021 Mar;3(3):e166-e168. doi: 10.1016/S2665-

- 9913(21)00007-2. Epub 2021 Jan 12.
- 388.** Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, **Antonelli A.** L-T4 Therapy in Enteric Malabsorptive Disorders. *Front Endocrinol (Lausanne)*. 2021 Feb 23;12:626371. doi: 10.3389/fendo.2021.626371. eCollection 2021.
- 389.** Benvenga S, Micali A, Ieni A, **Antonelli A**, Fallahi P, Pallio G, Irrera N, Squadrito F, Picciolo G, Puzzolo D, Minutoli L. The Association of Myo-Inositol and Selenium Contrasts Cadmium-Induced Thyroid C Cell Hyperplasia and Hypertrophy in Mice. *Front Endocrinol (Lausanne)*. 2021 Feb 25;12:608697. doi: 10.3389/fendo.2021.608697. eCollection 2021.
- 390.** **Antonelli A**, Elia G, Ragusa F, Paparo SR, Cavallini G, Benvenga S, Ferrari SM, Fallahi P. The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine. *Front Endocrinol (Lausanne)*. 2021 Mar 10;12:633587. doi: 10.3389/fendo.2021.633587. eCollection 2021.
- 391.** Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Patrizio A, Camastra S, Miccoli M, Cavallini G, Benvenga S, **Antonelli A.** Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy. *Front Endocrinol (Lausanne)*. 2021 Apr 16;12:654473. doi: 10.3389/fendo.2021.654473. eCollection 2021.
- 392.** Ferri C, Zignego AL, **Antonelli A.** Extrahepatic Manifestations of Chronic HCV Infection. *N Engl J Med*. 2021 Jul 1;385(1):94. doi: 10.1056/NEJMc2106143.
- 393.** Cristinziano L, Modestino L, **Antonelli A**, Marone G, Simon HU, Varricchi G, Galdiero MR. Neutrophil extracellular traps in cancer. *Semin Cancer Biol*. 2022 Feb;79:91-104. doi: 10.1016/j.semcancer.2021.07.011.
- 394.** **Antonelli A**, Fallahi P, Elia G, Ragusa F, Paparo SR, Mazzi V, Raimondo V, Ferrari SM, Ferri C. Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases. *Lancet Rheumatol*. 2021 Oct;3(10):e675-e676. doi: 10.1016/S2665-9913(21)00243-5.
- 395.** **Antonelli A**, Wartofsky L, Miccoli P. Editorial: Levothyroxine Therapy in Patients With Hypothyroidism. *Front Endocrinol (Lausanne)*. 2021 Jul 20;12:734895. doi: 10.3389/fendo.2021.734895.
- 396.** Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, Miccoli M, Galdiero MR, Varricchi G, Foddìs R, Guglielmi G, Spinelli C, La Motta C, Benvenga S, **Antonelli A**, Fallahi P. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. *Expert Opin Investig Drugs*. 2021 Sep;30(9):913-921. doi: 10.1080/13543784.2021.1972971. Epub 2021 Sep 6.
- 397.** Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Dagna L, Tavoni A, Caso F, Ursini F, Piero R, Caminiti M, Foti R, Ricciari V, Guiducci S, Pellegrini R, Zanatta E, Varcasia G, Olivo D, Gigliotti P, Cuomo G, Murdaca G, Cecchetti R, De Angelis R, Romeo N, Ingegnoli F, Cozzi F, Codullo V, Cavazzana I, Colaci M, Abignano G, De Santis M, Lubrano E, Fusaro E, Rossa AD, Spinella A, Lumetti F, De Luca G, Bellando-Randone S, Visalli E, Dal Bosco Y, Amato G, Giannini D, Bilia S, Masini F, Pellegrino G, Pigatto E, Generali E, Mariano GP, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Caminiti R, Scorpiniti D, Ferrari T, Campochiaro C, Brusi V, Fredi M, Moschetti L, Cacciapaglia F, Gragnani L, Monti M, Lorini S, Paparo SR, Ragusa F, Mazzi V, Elia G, Ferrari SM, Di Cola I, Vadacca M, Lorusso S, Barsotti S, Aprile ML, Marco T, Miccoli M, Bosello S, Matucci-Cerinic M, D'Angelo S, Doria A, Franceschini F, Meliconi R, Iannone F, Giacomelli R, Zignego AL, Varcasia P, **Antonelli A.** Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. *Curr Pharm Des*. 2021 Sep 2. doi: 10.2174/1381612827666210903103935. Online ahead of print.
- 398.** Andrea Nicolini, **Alessandro Antonelli.** New biological and immunological approaches to cancer therapy: Basic and clinical aspects. *Semin Cancer Biol*. 2022 Feb;79:1-3. doi: 10.1016/j.semcancer.2021.09.009.
- 399.** Raffaella Forleo, Giorgio Grani, Marco Alfò, Valentina Zilioli, Raffaele Giubbini, Maria Chiara Zatelli, Irene Gagliardi, Alessandro Piovesan, Alberto Ragni, Silvia Morelli, Efisio Puxeddu, Loredana Pagano, Maurilio Deandrea, Graziano Ceresini, Massimo Torlontano, Barbara Puligheddu, **Alessandro Antonelli**, Marco Centanni, Laura Fugazzola, Giovanna Spiazzi, Salvatore Monti, Ruth Rossetto, Fabio Monzani, Giovanni Tallini, Anna Crescenzi, Clotilde Sparano, Rocco Bruno, Andrea Repaci, Dario Tumino, Luciano Pezzullo, Celestino Pio Lombardi, Umberto Ferraro Petrillo, Sebastiano Filetti, Cosimo Durante, Maria Grazia Castagna. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). *Thyroid*. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248. Epub 2021 Oct 20.
- 400.** Enke Baldini, Chiara Tuccilli, Daniele Pironi, Antonio Catania, Francesco

Tartaglia, Filippo Maria Di Matteo, Piergaspare Palumbo, Stefano Arcieri, Domenico Mascagni, Giorgio Palazzini, Domenico Tripodi, Alessandro Maturo, Massimo Vergine, Danilo Tarroni, Eleonora Lori, Iulia Catalina Ferent, Corrado De Vito, Poupak Fallahi, **Alessandro Antonelli**, Simona Censi, Matteo D'Armiento, Susy Barollo, Caterina Mian, Aldo Morrone, Vito D'Andrea, Salvatore Sorrenti, Salvatore Ulisse. Expression and Clinical Utility of Transcription Factors Involved in Epithelial-Mesenchymal Transition during Thyroid Cancer Progression. *J Clin Med*. 2021 Sep 9;10(18):4076. doi: 10.3390/jcm10184076.

401. Armando Patrizio, Silvia Martina Ferrari, **Alessandro Antonelli**, Poupak Fallahi. A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. *J Autoimmun*. 2021 Dec;125:102738. doi: 10.1016/j.jaut.2021.102738.

402. Raymond S Douglas, George J Kahaly, Shoaib Ugradar, Heike Elflein, Katharina A Ponto, Brian T Fowler, Roger Dailey, Gerald J Harris, Jade Schiffman, Rosa Tang, Sara Wester, Amy Patel Jain, Claudio Marcocci, Michele Marinò, **Alessandro Antonelli**, Anja Eckstein, Dagmar Führer-Sakel, Mario Salvi, Saba Sile, Megan Francis-Sedlak, Robert J Holt, Terry J Smith. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. *Ophthalmology*. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017.

403. Giusy Elia, Poupak Fallahi, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Salvatore Benvenga, **Alessandro Antonelli**, Silvia Martina Ferrari. Precision Medicine in Graves' Disease and Ophthalmopathy. *Front Pharmacol*. 2021 Oct 28;12:754386. doi: 10.3389/fphar.2021.754386. eCollection 2021.

404. **Antonelli A**, Ferri C. Covid-19 Epidemiology, Pathogenesis and Therapy. *Curr Pharm Des*. 2021;27(41):4195-4196. doi: 10.2174/138161282741211020101212.

405. Ferri C, Ursini F, Gragnani L, Raimondo V, Giuggioli D, Foti R, Caminiti M, Olivo D, Cuomo G, Visentini M, Cacciapaglia F, Pellegrini R, Pigatto E, Urraro T, Naclerio C, Tavoni A, Puccetti L, Varcasia G, Cavazzana I, L'Andolina M, Ruscitti P, Vadacca M, Gigliotti P, La Gualana F, Cozzi F, Spinella A, Visalli E, Dal Bosco Y, Amato G, Masini F, Pagano Mariano G, Brittelli R, Aiello V, Caminiti R, Scorpiniti D, Rechichi G, Ferrari T, Monti M, Elia G, Franceschini F, Meliconi R, Casato M, Iannone F, Giacomelli R, Fallahi P, Santini SA, Zignego AL, **Antonelli A**. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. *J Autoimmun*. 2021 Dec;125:102744. doi: 10.1016/j.jaut.2021.102744. Epub 2021 Nov 10.

406. Salvatore Benvenga, **Alessandro Antonelli**, Poupak Fallahi, Carmen Bonanno, Carmelo Rodolico, Fabrizio Guarneri. Amino acid sequence homology between thyroid autoantigens and central nervous system proteins: Implications for the steroid-responsive encephalopathy associated with autoimmune thyroiditis. *J Clin Transl Endocrinol*. 2021 Nov 6;26:100274. doi: 10.1016/j.jcte.2021.100274. eCollection 2021 Dec.

407. Ferrari SM, Ragusa F, Elia G, Paparo SR, Mazzi V, Baldini E, Benvenga S, **Antonelli A**, Fallahi P. Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism. *Front Pharmacol*. 2021 Nov 17;12:750380. doi: 10.3389/fphar.2021.750380. eCollection 2021.

408. Giusy Elia, Silvia Martina Ferrari, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Salvatore Ulisse, Salvatore Benvenga, **Alessandro Antonelli**, Poupak Fallahi. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. *Expert Opin Pharmacother*. 2022 Jan 21;1-12. doi: 10.1080/14656566.2022.2030704. Online ahead of print.

409. **Alessandro Antonelli**. Drug Discovery. *Editorial Curr Pharm Des*. 2022;28(3):179. doi: 10.2174/1381612828666220103172626.

410. Claudio Spinelli, Marco Ghionzoli, Alessia Bertocchini, Beatrice Sanna, Carlotta Plessi, Silvia Strambi, Luigi De Napoli, Gianluca Frustaci, Gabriele Materazzi, **Alessandro Antonelli**, Riccardo Morganti, Fabrizio Gennari, Alessandro Inserra, Gianni Bisogno, Piergiorgio Gamba, Andrea Ferrari, Maura Massimino. Factors associated with postoperative hypocalcemia following thyroidectomy in childhood. *Pediatr Blood Cancer*. 2022 Aug;69(8):e29576. doi: 10.1002/pbc.29576. Epub 2022 Feb 7.

411. Patrizio, A., Ferrari, S. M., **Antonelli, A.**, & Fallahi, P. (2022). Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA

- vaccination. Autoimmunity reviews, 103096. doi: 10.1016/j.autrev.2022.103096.
- 412.** Armando Patrizio, Poupak Fallahi, **Alessandro Antonelli**, Silvia Martina Ferrari. Immune Checkpoint Inhibitor-Induced Thyroid Disorders: a Single Center Experience. *Curr Pharm Des.* 2023;29(4):295-299. doi: 10.2174/1381612828666220518151509.
- 413.** Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, Valeria Mazzi, Giovanni Guglielmi, Rudy Foddìs, Claudio Spinelli, Salvatore Ulisse, **Alessandro Antonelli**, Poupak Fallahi. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. *Int J Mol Sci.* 2022 May 20;23(10):5731. doi: 10.3390/ijms23105731.
- 414.** Ilaria Stramazzo, Silvia Capriello, **Alessandro Antonelli**, Poupak Fallahi, Marco Centanni, Camilla Virili. Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer. *Hormones (Athens).* 2022 Dec;21(4):537-543. doi: 10.1007/s42000-022-00376-9. Epub 2022 Jun 2.
- 415.** Salvatore Benvenga, Fausto Famà, Laura Giovanna Perdichizzi, **Alessandro Antonelli**, Gabriela Brenta, Francesco Vermiglio, Mariacarla Moleti. Fish and the Thyroid: A Janus Bifrons Relationship Caused by Pollutants and the Omega-3 Polyunsaturated Fatty Acids. *Front Endocrinol (Lausanne).* 2022 May 27;13:891233. doi: 10.3389/fendo.2022.891233. eCollection 2022.
- 416.** Ferri C, Raimondo V, Gragnani L, Giuggioli D, Dagna L, Tavoni A, Ursini F, L'Andolina M, Caso F, Ruscitti P, Caminiti M, Foti R, Ricciari V, Guiducci S, Pellegrini R, Zanatta E, Varcasia G, Olivo D, Gigliotti P, Cuomo G, Murdaca G, Cecchetti R, De Angelis R, Romeo N, Ingegnoli F, Cozzi F, Codullo V, Cavazzana I, Colaci M, Abignano G, De Santis M, Lubrano E, Fusaro E, Spinella A, Lumetti F, De Luca G, Bellando-Randone S, Visalli E, Bosco YD, Amato G, Giannini D, Bilia S, Masini F, Pellegrino G, Pigatto E, Generali E, Mariano GP, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Caminiti R, Scorpiniti D, Ferrari T, Campochiaro C, Brusi V, Fredi M, Moschetti L, Cacciapaglia F, Paparo SR, Ragusa F, Mazzi V, Elia G, Ferrari SM, Di Cola I, Vadacca M, Lorusso S, Monti M, Lorini S, Aprile ML, Tasso M, Miccoli M, Bosello S, D'Angelo S, Doria A, Franceschini F, Meliconi R, Matucci-Cerinic M, Iannone F, Giacomelli R, Salvarani C, Zignego AL, Fallahi P, **Antonelli A**. Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. *Curr Pharm Des.* 2022;28(24):2022–2028. doi: 10.2174/1381612828666220614151732.
- 417.** Torregrossa L, Poma AM, Macerola E, Rago T, Vignali P, Romani R, Proietti A, Di Stefano I, Scuotri G, Ugolini C, Basolo A, **Antonelli A**, Materazzi G, Santini F, Basolo F. The Italian Consensus for the Classification and Reporting of Thyroid Cytology: Cytohistologic and molecular correlations on 37,371 nodules from a single institution. *Cancer Cytopathol.* 2022 Nov;130(11):899-912. doi: 10.1002/cncy.22618.
- 418.** Paparo SR, Ferrari SM, Patrizio A, Elia G, Ragusa F, Botrini C, Balestri E, Guarneri F, Benvenga S, **Antonelli A**, Fallahi P. Myoinositol in Autoimmune Thyroiditis. *Front Endocrinol (Lausanne).* 2022 Jun 28;13:930756. doi: 10.3389/fendo.2022.930756. eCollection 2022
- 419.** Ferri C, Gragnani L, Raimondo V, Visentini M, Giuggioli D, Lorini S, Foti R, Cacciapaglia F, Caminiti M, Olivo D, Cuomo G, Pellegrini R, Pigatto E, Urraro T, Naclerio C, Tavoni A, Puccetti L, Cavazzana I, Ruscitti P, Vadacca M, La Gualana F, Cozzi F, Spinella A, Visalli E, Bosco YD, Amato G, Masini F, Mariano GP, Brittelli R, Aiello V, Scorpiniti D, Rechichi G, Varcasia G, Monti M, Elia G, Franceschini F, Casato M, Ursini F, Giacomelli R, Fallahi P, Santini SA, Iannone F, Salvarani C, Zignego AL, **Antonelli A**. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases. *J Autoimmun.* 2022 Jul;131:102866. doi: 10.1016/j.jaut.2022.102866. Epub 2022 Jul 11.
- 420.** Capriello S, Ferrari SM, Gatto I, Santaguida MG, Fallahi P, **Antonelli A**, Mangino G, Romeo G, Virili C, Centanni M. Regulatory B Cells in Systemic Sclerosis Isolated or Concomitant With Hashimoto Thyroiditis. *Front Immunol.* 2022 Jul 6;13:921260. doi: 10.3389/fimmu.2022.921260.
- 421.** Fallahi P, Ferrari SM, Elia G, Paparo SR, Patrizio A, Balestri E, Mazzi V, Gragnani L, Ferri C, Botrini C, Ragusa F, **Antonelli A**. Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series. *Autoimmun Rev.*

2022 Nov;21(11):103183. doi: 10.1016/j.autrev.2022.103183. Epub 2022 Aug 23.

422. Spinelli C, Ghionzoli M, Oreglio C, Sanna B, De Napoli L, Morganti R, **Antonelli A**, Morabito A, Miccoli P. Increased trend of thyroid cancer in childhood over the last 30 years in EU countries: a call for the pediatric surgeon. *Eur J Pediatr.* 2022 Nov;181(11):3907-3913. doi: 10.1007/s00431-022-04596-4. Epub 2022 Aug 31.

423. Gragnani L, Visentini M, Lorini S, La Gualana F, Santini SA, Cacciapaglia F, Tavoni A, Cuomo G, Fallahi P, Iannone F, **Antonelli A**, Casato M, Zignego AL, Ferri C. COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies. *J Transl Autoimmun.* 2022;5:100164. doi: 10.1016/j.jtauto.2022.100164. Epub 2022 Sep 13.

424. Patrizio A, Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, **Antonelli A**, Fallahi P. Graves' Disease Following SARS-CoV-2 Vaccination: A Systematic Review. *Vaccines (Basel).* 2022 Sep 1;10(9):1445. doi: 10.3390/vaccines10091445.

425. Patrizio A, Viva T, Ferrari SM, Elia G, Ragusa F, Paparo SR, **Antonelli A**, Fallahi P. Graves' disease induced by IFN- β 1a therapy: A case report, review of literature and new insights into the pathogenesis. *Autoimmun Rev.* 2023 Feb;22(2):103238. doi: 10.1016/j.autrev.2022.103238.

426. Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, Botrini C, Rugani L, Benvenga S, Materazzi G, Spinelli C, **Antonelli A**, Fallahi P, Ferrari SM. Molecular features of aggressive thyroid cancer. *Front Oncol.* 2022 Dec 20;12:1099280. doi: 10.3389/fonc.2022.1099280.

427. Fallahi P, Ragusa F, Paparo SR, Elia G, Balestri E, Mazzi V, Patrizio A, Botrini C, Benvenga S, Ferrari SM, **Antonelli A**. Teprotumumab for the treatment of thyroid eye disease. *Expert Opin Biol Ther.* 2023 Feb;23(2):123-131. doi: 10.1080/14712598.2023.2172328.

428. Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, Patrizio A, Piaggi S, Baldini E, Centanni M, La Motta C, **Antonelli A**, Fallahi P. Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture. *Int J Mol Sci.* 2023 Jan 25;24(3):2398. doi: 10.3390/ijms24032398.

429. Gragnani L, Visentini M, Lorini S, Santini SA, Lauletta G, Mazzaro C, Urraro T, Quartuccio L, Cacciapaglia F, Ruscitti P, Tavoni A, Marri S, Cusano G, Petraccia L, Naclerio C, Treppo E, Del Frate G, Di Cola I, Raimondo V, Scorpiniti D, Monti M, Puccetti L, Elia G, Fallahi P, Basili S, Scarpato S, Iannone F, Casato M, **Antonelli A**, Zignego AL, Ferri C. COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity. *J Clin Immunol.* 2023 May;43(4):680-691. doi: 10.1007/s10875-023-01444-4.

430. Grani G, Gentili M, Siciliano F, Albano D, Zilioli V, Morelli S, Puxeddu E, Zatelli MC, Gagliardi I, Piovesan A, Nervo A, Crocetti U, Massa M, Samà MT, Mele C, Deandrea M, Fugazzola L, Puligheddu B, **Antonelli A**, Rossetto R, D'Amore A, Ceresini G, Castello R, Solaroli E, Centanni M, Monti S, Magri F, Bruno R, Sparano C, Pezzullo L, Crescenzi A, Mian C, Tumino D, Repaci A, Castagna MG, Triggiani V, Porcelli T, Meringolo D, Locati L, Spiazzi G, Di Dalmazi G, Anagnostopoulos A, Leonardi S, Filetti S, Durante C. A data-driven approach to refine predictions of differentiated thyroid cancer outcomes: a prospective multicenter study. *J Clin Endocrinol Metab.* 2023 Jul 14;108(8):1921-1928. doi: 10.1210/clinem/dgad075.

431. Buscemi S, Davoli C, Trecarichi EM, Morrone HL, Tassone B, Buscemi C, Randazzo C, Barile AM, Colombrita P, Soresi M, Giannitrapani L, Cascio A, Scichilone N, Cottone C, Sbraccia P, Guglielmi V, Leonetti F, Malavazos AE, Basilico S, Carruba M, Santini F, **Antonelli A**, Viola N, Romano M, Cesana BM, Torti C. The three facets of the SARS-CoV-2 pandemic during the first two waves in the northern, central, and southern Italy. *J Infect Public Health.* 2023 Feb 7;16(4):520-525. doi: 10.1016/j.jiph.2023.02.002.

432. Ferrari SM, Paparo SR, Ragusa F, Elia G, Mazzi V, Patrizio A, Ghionzoli M, Varricchi G, Centanni M, Ulisse S, **Antonelli A**, Fallahi P. Chemokines in thyroid autoimmunity. *Best Pract Res Clin Endocrinol Metab.* 2023 Mar;37(2):101773. doi: 10.1016/j.beem.2023.101773. Epub 2023 Mar 9.

433. Gagliardi F, Baldini E, Lori E, Cardarelli S, Pironi D, Lauro A, Tripodi D, Palumbo P, D'Armiento E, Cavallaro G, Polistena A, D'Orazi V, Sibio S, Fallahi P, **Antonelli A**, D'Andrea V, Ulisse S, Sorrenti S. Insights on the Association between Thyroid Diseases and Colorectal Cancer. *J Clin Med.* 2023 Mar 13;12(6):2234. doi: 10.3390/jcm12062234.

434. Patrizio A, Ferrari SM, Stoppini G, Palmisano E, Elia G, Ragusa F, Paparo SR, Balestri E, Mazzi V, Botrini C, Proietti A, Famà F, Benvenga S, **Antonelli A**, Fallahi P. Thyroid Metastasis from Primary Breast Cancer. *J Clin Med*. 2023 Apr 4;12(7):2709. doi: 10.3390/jcm12072709.
435. Bruschi F, Pinto B, Fallahi P, Ferrari SM, **Antonelli A**. Increased neutrophil derived chemokines (CXCL10 and CCL2) in human trichinellosis as possible serological markers of the polarization of the immune response against the parasite. *Cytokine*. 2023 Jun;166:156205. doi: 10.1016/j.cyto.2023.156205. Epub 2023 Apr 12. PMID: 37058963.
436. Spinelli C, Ghionzoli M, Sahli LI, Guglielmo C, Frascella S, Romano S, Ferrari C, Gennari F, Conzo G, Morganti R, De Napoli L, Quaglietta L, De Martino L, Picariello S, Grandone A, Luongo C, Gambale A, Patrizio A, Fallahi P, **Antonelli A**, Ferrari SM. DICER1 Syndrome: A Multicenter Surgical Experience and Systematic Review. *Cancers (Basel)*. 2023 Jul 19;15(14):3681. doi: 10.3390/cancers15143681.
437. Brenta G, Nepote A, Barreto A, Musso C, Faingold C, Fossati P, **Antonelli A**, Fallahi P, Famà F, Meroño T. Low glomerular filtration rate values are associated with higher TSH in an elderly population at high cardiovascular disease risk. *Front Endocrinol (Lausanne)*. 2023 Aug 16;14:1162626. doi: 10.3389/fendo.2023.1162626.
438. Modestino L, Cristinziano L, Poto R, Ventrici A, Trocchia M, Ferrari SM, Fallahi P, Paparo SR, Marone G, **Antonelli A**, Varricchi G, Galdiero MR. Neutrophil extracellular traps and neutrophil-related mediators in human thyroid cancer. *Front Immunol*. 2023 Aug 29;14:1167404. doi: 10.3389/fimmu.2023.1167404.
439. De Leo S, D'Elia S, Grani G, Dondi F, Bertagna F, Puxeddu E, Morelli S, Piovesan A, Nervo A, Zatelli MC, Gagliardi I, Samà MT, Aimaretti G, Crocetti U, Massa M, Deandrea M, Retta F, Pagano L, Rossi M, Solaroli E, Pezzullo L, Chiofalo MG, Pontecorvi A, Lombardi CP, **Antonelli A**, Patrizio A, Messuti I, Magri F, Spiazzi G, Ceresini G, Bruno R, Sparano C, Centanni M, Crescenzi A, Tallini G, Marotta V, Madeo B, Mian C, Filetti S, Durante C, Fugazzola L. A Prospective, Multicenter Study Examining the Relationship between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis. *Thyroid*. 2023 Nov;33(11):1318-1326. doi: 10.1089/thy.2023.0052.
440. Fallahi P, Elia G, Ragusa F, Paparo SR, Patrizio A, Balestri E, Mazzi V, Benvenga S, Varricchi G, Gragnani L, Botrini C, Baldini E, Centanni M, Ferri C, **Antonelli A**, Ferrari SM. Thyroid Autoimmunity and SARS-CoV-2 Infection. *J Clin Med*. 2023 Oct 5;12(19):6365. doi: 10.3390/jcm12196365.
441. Ferri C, Raimondo V, Giuggioli D, Gragnani L, Lorini S, Dagna L, Bosello SL, Foti R, Ricciari V, Guiducci S, Cuomo G, Tavoni A, De Angelis R, Cacciapaglia F, Zanatta E, Cozzi F, Murdaca G, Cavazzana I, Romeo N, Codullo V, Pellegrini R, Varcasia G, De Santis M, Selmi C, Abignano G, Caminiti M, L'Andolina M, Olivo D, Lubrano E, Spinella A, Lumetti F, De Luca G, Ruscitti P, Urraro T, Visentini M, Bellando-Randone S, Visalli E, Testa D, Sciascia G, Masini F, Pellegrino G, Saccon F, Balestri E, Elia G, Ferrari SM, Tonutti A, Dall'Ara F, Pagano Mariano G, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Dal Bosco Y, Foti R, Di Cola I, Scorpiniti D, Fusaro E, Ferrari T, Gigliotti P, Campochiaro C, Francioso F, Iandoli C, Caira V, Zignego AL, D'Angelo S, Franceschini F, Matucci-Cerinic M, Giacomelli R, Doria A, Santini SA, Fallahi P, Iannone F, **Antonelli A**; COVID-19 & ASD Italian Study Group. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase. *J Transl Autoimmun*. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212.
442. Spinelli C, Ghionzoli M, Guglielmo C, Baroncelli G, Tyutyusheva N, Frega A, Patrizio A, Fallahi P, Ferrari SM, **Antonelli A**. Hypoparathyroidism Associated with Benign Thyroid Nodules in DiGeorge-like Syndrome: A Rare Case Report and Literature Review. *Endocr Metab Immune Disord Drug Targets*. 2023 Nov 17. doi: 10.2174/0118715303274582231102094440.
443. Fallahi P, Patrizio A, Stoppini G, Elia G, Ragusa F, Paparo SR, Balestri E, Mazzi V, Botrini C, Varricchi G, Ulisse S, Ghionzoli M, **Antonelli A**, Ferrari SM. Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review. *Curr Oncol*. 2023 Nov 30;30(12):10237-10248. doi: 10.3390/curroncol30120745.
444. Baldini E, Cardarelli S, Campese AF, Lori E, Fallahi P, Virili C, Forte F, Pironi D, Di Matteo FM, Palumbo P, Costanzo ML, D'Andrea V, Centanni M,

Sorrenti S, **Antonelli A**, Ulisse S. Evaluation of the Therapeutic Effects of Harmine on Anaplastic Thyroid Cancer Cells. Int J Mol Sci. 2024 Jan 17;25(2):1121. doi: 10.3390/ijms25021121.

(Impact Factor >1700), H index 84 (Scopus and ISI, ASN).

Altre dichiarazioni

E' stato **CHAIRMAN e INVITED SPEAKER** in congressi internazionali e ha tenuto lezioni presso Università Europee e Americane.

E' **MEMBRO DI ASSOCIAZIONI SCIENTIFICHE INTERNAZIONALI** (The Endocrine Society, European Thyroid Association, American Thyroid Association, New York Academy of Sciences, Royal Society of Medicine, Italian Endocrine Association, etc.).

E' stato membro del comitato per la stesura delle linee guida dell'American Thyroid Association (dicembre 2019-ottobre 2022).

È stato consulente per Horizon Therapeutics Italy S.r.l. (dal 02 febbraio 2023 al 01 febbraio 2024).

E' stato consultato come esperto alla riunione di Joint Research Centre (JRC) of the European Commission - Expert Meeting on chemical selection for the EU-NETVAL thyroid validation study (ISPRA, 21-22 Novembre 2019).

MEMBRO DI EDITORIAL BOARD

- Membro dell'Editorial Board di Drugs (censito su Scopus e Web of Science, IF = 11.5)
- Membro dell'Editorial Board di International Journal of Molecular Sciences (Scopus and Web of Science, IF = 5.6)
- Editor Associato di Frontiers in Endocrinology | Thyroid Endocrinology (Scopus and Web of Science, IF = 5.2)
- Membro dell'Editorial Board di Current Genomics (Scopus and Web of Science, IF = 2.6)
- Membro dell'Editorial Board di Gland Surgery (Scopus and Web of Science, IF = 1.8)
- Membro dell'Editorial Board di Molecular Medicine Reports - Spandidos Publication (Scopus and Web of Science, IF = 3.4)
- Membro dell'Editorial Board di Experimental and Therapeutic Medicine - Spandidos Publications (Scopus and Web of Science, IF = 2.7)
- Membro dell'Editorial Board di Recent Patents on Inflammation & Allergy Drug Discovery (Scopus)
- Membro dell'Editorial Board di World Journal of Meta-Analysis
- Membro dell'Editorial Board di Hormonal Studies (Senior Editor)
- Membro dell'Editorial Board di Journal of Thyroid disorders and Therapy
- Editor Associato di International Journal of Medical Devices and Adjuvant Treatments
- Membro dell'Editorial Board di Current Pharmacogenomics and Personalized Medicine (Scopus)
- Membro dell' Editorial Academy di International Journal of Oncology (Scopus and Web of Science, IF = 5.2)
- Membro dell'Editorial Advisory Panel di World Academy of Sciences Journal - Spandidos Publications
- **Editor in Chief di Current Pharmaceutical Design (Scopus and Web of Science Impact Factor: 3.1)**

E' revisore per le seguenti riviste scientifiche internazionali:

E' **revisore** per le seguenti riviste scientifiche internazionali: Annals of

Internal Medicine, The Journal of Clinical Endocrinology & Metabolism; Nature Endocrinology; JAMA; Diabetes; Diabetes Care; Arthritis Care & Research, Arthritis Research, Atherosclerosis, BMC Pediatrics, British Journal of Cancer, Adis Drug Clinical Q&A, Advances in Medical Sciences, Annals, Academy of Medicine, Singapore, Archivum Immunologiae et Therapiae Experimentalis, British Journal of Dermatology, Cancer Chemotherapy and Pharmacology, Cancer Research, Case Reports in Neurological Medicine, Case Reports in Radiology, Cell Biochemistry & Function, Clinical and Developmental Immunology, Clinical and Experimental Dermatology, Clinical and Experimental Immunology, Clinical and Experimental Medicine, Clinical and Experimental Rheumatology, Clinical and Investigative Medicine, Clinical Biochemistry, Clinical Cancer Research, Clinical Endocrinology, Clinical Immunology, Cytokine, Diabetologia, Disease Markers, Drugs, Endocrine, Endocrine-Related Cancer, Endocrinology & Metabolic Syndrome: Current Research, European Journal of Clinical Investigation, European Journal of Endocrinology, European Journal of Gastroenterology & Hepatology, European Journal of Internal Medicine, Expert Opinion On Therapeutic Targets, Expert Review of Anticancer Therapy, Frontiers in Thyroid Endocrinology, Hepatology, Hepatitis Research and Treatment, Hormone and Metabolic Research, Hormones, Human Immunology, Immunobiology, Indian Journal of Medical Research, Inflammation, Journal of Clinical Apheresis, International Journal of Clinical Practice, International Journal of Endocrinology, International Journal of Immunopathology and Pharmacology, Journal of Clinical Immunology, Journal of Gastroenterology and Hepatology, Journal of Neurology, Journal of Proteome Research, Journal of Thyroid Research, Journal of Surgical Oncology, Journal of the European Academy of Dermatology and Venereology, Journal of the Saudi Heart Association, Journal of Viral Hepatitis, Lupus, Medicine, Memórias do Instituto Oswaldo Cruz, Metabolism, Molecular and Cellular, Endocrinology, Pediatric Diabetes, Pediatrics, Plos One, QJM, Recent Patents on DNAG and Gene Sequence, Recent Patents On Endocrine, Metabolic & Immune Drug Discovery, Recent Patents on Inflammation & Allergy Drug Discovery, Scandinavian Journal of Gastroenterology, Scandinavian Journal of Rheumatology, The Journal of Rheumatology, Therapeutics and Clinical Risk Management, Thyroid, Tumori, World Journal of Gastroenterology, World Journal of Gastrointestinal Pathophysiology, Yonsei Medical Journal.

Ulteriori informazioni

Revisore per:

- Commissione Affari Sociali della Camera su tematiche sanitarie epidemiologiche.
- Comitato di Indirizzo per la Valutazione della Ricerca, presso il Ministero dell'Università e della Ricerca.
- Valutazione dei Bandi FIRB - Programma "Futuro in Ricerca", presso il Ministero dell'Università e della Ricerca.
- Valutazione dei Bandi PRIN, presso il Ministero dell'Università e della Ricerca.
- Valutazione VQR, presso il Ministero dell'Università e della Ricerca.
- Organismi di ricerca internazionali:
 - The Netherlands Organization for Health Research and Development (PROJECT-2012);
 - Institute For Biomedical Research, University of Birmingham (PROJECT-2011);
 - Kuwait University (PROJECT-2010).
 - Austrian Science Fund (FWF)
 - KWF Kankerbestrijding (Dutch Cancer Society)
 - UAEU Research Grant System.
 - Research Grants Council, Hong Kong, China
 - Diabetes UK Research Office